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The reciprocal interplay of cancer cells and host cells is an indispensable prerequisite for 
tumor growth and progression. Cells of both the innate and adaptive immune system, 
in particular tumor-associated macrophages (TAMs) and T cells, as well as cancer- 
associated fibroblasts enter into a malicious liaison with tumor cells to create a 
tumor-promoting and immunosuppressive tumor microenvironment (TME). Ovarian 
cancer, the most lethal of all gynecological malignancies, is characterized by a unique 
TME that enables specific and efficient metastatic routes, impairs immune surveillance, 
and mediates therapy resistance. A characteristic feature of the ovarian cancer TME 
is the role of resident host cells, in particular activated mesothelial cells, which line the 
peritoneal cavity in huge numbers, as well as adipocytes of the omentum, the preferred 
site of metastatic lesions. Another crucial factor is the peritoneal fluid, which enables the 
transcoelomic spread of tumor cells to other pelvic and peritoneal organs, and occurs 
at more advanced stages as a malignancy-associated effusion. This ascites is rich in 
tumor-promoting soluble factors, extracellular vesicles and detached cancer cells as 
well as large numbers of T cells, TAMs, and other host cells, which cooperate with 
resident host cells to support tumor progression and immune evasion. In this review, we 
summarize and discuss our current knowledge of the cellular and molecular interactions 
that govern this interplay with a focus on signaling networks formed by cytokines, lipids, 
and extracellular vesicles; the pathophysiologial roles of TAMs and T cells; the mecha-
nism of transcoelomic metastasis; and the cell type selective processing of signals from 
the TME.
Keywords: tumor microenvironment, ascites, tumor-associated macrophage, T cell checkpoints, extracellular 
vesicles, invasion, STAT, NFκB, adhesion, metastasis, mesothelial cell, T cell
Abbreviations: APC, antigen-presenting cell; CAA, cancer-associated adipocyte; CAF, cancer-associated fibroblast; DC, 
dendritic cell; EC, endothelial cell; EV, extracellular microvesicle; IFN, interferon; IL, interleukin; HGSOC, high-grade 
serous ovarian carcinoma; MDSC, myeloid-derived suppressor cell; NK cell, natural killer cell; SIP, sphingosine-1-phosphate; 
STAT, signal transducer and activator of transcription; STIC, serous tubal intraepithelial carcinoma; TAM, tumor-associated 
macrophage; TGFβ, transforming growth factor β; TIL, tumor-infiltrating lymphocyte; TLR, Toll-like receptor; TME, tumor 
microenvironment; Treg, T regulatory cell; VEGF, vascular endothelial growth factor.
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BiOLOGiCAL AND CLiNiCAL FeATUReS 
OF OvARiAN CARCiNOMA
Ovarian cancer is the deadliest of all gynecological malignancies 
with >60,000 new cases reported annually in the United States 
and the European Union (1). More than 90% of malignant ovar-
ian tumors are carcinomas, presumably originating from the 
ovarian surface epithelium and/or the fallopian tube. Ovarian 
cancer has a dire prognosis with an overall 5-year survival rate 
of <40%. The WHO classification distinguishes six major enti-
ties of ovarian tumors, i.e., serous, mucinous, endometrioid, 
clear cell, transitional cell, and squamous carcinoma (1), with 
high-grade serous ovarian carcinoma (HGSOC) representing 
the most common subtype. The majority of patients present with 
advanced stage disease and tumor masses in the abdomen beyond 
the pelvis, contributing to the disastrous prognosis of the disease. 
HGSOC is characterized by a very high frequency of TP53 muta-
tions (97%), germline and somatic BRCA1/2 mutations (~40%), 
as well as amplification and overexpression of MYC (>50%) (2).
According to the prevailing opinion, HGSOCs arise from the 
fimbriated fallopian tube epithelium (3). There is some evidence 
to suggest that serous tubal intraepithelial carcinomas (STICs) are 
precursor lesion of HGSOC, although recent evidence obtained 
by next-generation sequencing suggests that lesions histologically 
identified as STICs may actually represent micrometastases (4). 
Several features contribute to the fatal nature of HGSOC, which 
distinguish it from other human cancers, in particular, the role of 
the peritoneal fluid in cancer cell spread:
• Tumor cells can be shed at a very early stage of the disease. 
Even at a stage when the primary tumor is still confined to the 
ovary, cancer cells can be detected in peritoneal lavage fluid.
• Besides hematogenous dissemination to the omentum (5), the 
spread of tumor cells to other pelvic and peritoneal organs is 
facilitated by the peritoneal fluid serving as a carrier (6). This 
transcoelomic dissemination is a major route for the adhesion 
of cancer cells to the omentum and serous membranes lining 
the peritoneal organs, giving rise to metastatic lesions growing 
into the peritoneal cavity rather than invading through the 
lamina propria (6, 7).
• The peritoneal environment, which is frequently formed by the 
effusion building up in the peritoneal cavity (ascites), is rich 
in tumor-promoting soluble factors (8), extracellular vesicles 
(9), highly tumorigenic cancer cells (10), and different types 
of immune cells, including large numbers of different types 
of T cells (11), tumor-associated macrophages (TAMs) (12, 
13), and other host cells, supporting tumor cell proliferation, 
progression, chemoresistance, and immune evasion (14–16).
• In contrast to most other cancers, metastases at distant sites are 
confined to late stages (6). The most serious problem for most 
HGSOC patients is recurrent, aggressive growth of metastatic 
lesions within the peritoneal cavity.
Mechanisms of Therapy Failure
Although HGSOC is typically highly sensitive to chemotherapy, 
a small subgroup (<10%) is refractory to first-line therapy, 
pointing to a mechanism of inherent resistance. However, even 
after a clinical remission, most patients suffer from a relapse of 
the disease (1). While some of these patients are refractory to 
chemotherapy due to acquired chemoresistance, the majority 
undergo remission under the same treatment regimen. This 
regrowth of lesions displaying a similar chemosensitivity as the 
primary disease points to a mechanism of therapy failure that 
is fundamentally different form intrinsic or acquired resistance. 
However, the mechanisms underlying this transient chemoresist-
ance are unknown.
A number of studies have associated chemoresistance with 
epithelial–mesenchymal transition (EMT), cell cycle arrest, 
blocked apoptosis, drug efflux, and several signaling pathways, 
including TGFβ, WNT, and NOTCH, but these observations did 
not yield a deep understanding of the mechanisms leading to 
relapse of the disease (17). It has also been a topic of intense 
research to clarify whether the regrowth of tumors after a 
complete clinical response is caused by a small population of 
cancer stem cells that are endowed with stem-like properties 
(18–20). However, multiple studies showed that ovarian cancer 
cell subpopulations express stemness markers at highly variable 
levels in different combinations and with none of these markers 
being obligatory (21–26). These findings suggest that a common 
or early ovarian cancer stem cell may not exist or has not been 
identified yet.
Comprehensive genomic studies by The Cancer Genome 
Atlas (TCGA) consortium have confirmed the prevalence of the 
genetic alterations described earlier and identified a number of 
recurrent, but infrequent changes (2). A more recent study has 
identified PTEN loss as another common driver event associ-
ated with a poor prognosis (27). This study also defined four 
transcriptional subtypes of ovarian carcinoma (differentiated, 
proliferative, immunoreactive, and mesenchymal), which were, 
however, not associated with differences in survival. In contrast, 
a recent reanalysis of the TCGA data indicated a favorable 
outcome for the immunoreactive subtype, presumably due 
to partial antitumor immune response (28). However, new 
insights into the precise mechanisms of chemoresistance were 
not gained by these studies. Whole-genome sequencing of DNA 
from patients with primary refractory, sensitive, and matched 
acquired resistant disease suggested that (i) inactivation of 
the tumor suppressor genes RB1, NF1, RAD51B, and PTEN, 
(ii) reversions of germline BRCA1/2 mutations or loss of BRCA1 
promoter methylation, and (iii) overexpression of MDR1 are 
associated with, and may contribute to, acquired chemotherapy 
resistance (29). In contrast, amplification of CCNE1 was fre-
quently observed in primary refractory cancer. However, these 
findings have not been linked to therapy failure or chemoresist-
ance. Finally, a microarray study published in 2005 (30) identi-
fied an 11-gene signature characteristic of relapsed HGSOC, but 
mechanistic links to therapy resistance remain hypothetical.
It has been suggested that treatment failure is caused, in part, 
by cells escaping chemotherapy-induced cell death by entering 
a transient state of resistance, e.g., by entering a non-cycling 
state with low metabolic activity. This is a characteristic feature 
of detached tumor cells and spheroids floating in the peritoneal 
fluid or ascites. However, tumor cells surviving chemotherapy 
can trigger disease recurrence only if they are able to invade 
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the peritoneum or omentum to establish proliferative lesions. 
Therefore, cancer cell adhesion to, and invasion of, the meso-
thelial cell layer lining these organs, and thus the mechanisms 
of transcoelomic dissemination appear to be central aspects of 
therapy failure. Conditional resistance can also be modulated by 
interactions with host cells (31–33), whose presence and func-
tional states are spatially and temporally highly heterogeneous.
THe CeLLULAR MiCROeNviRONMeNT 
AND CYTOKiNe SiGNALiNG NeTwORK 
OF OvARiAN CANCeR ASCiTeS
Ascites-associated cancer cells occur as single cells or multicel-
lular spheroids and are likely to be responsible for peritoneal 
dissemination and to contribute to relapse of the disease (34). 
Besides these tumor cells, macrophages and T cells are the most 
common cell types in ovarian carcinoma-associated ascites, but 
other host cells are also present to a variable extent, including 
natural killer (NK) cells, fibroblasts, adipocytes, and mesothelial 
cells (15, 35, 36). Cytokines and growth factors released by these 
cells into the tumor microenvironment (TME) play essential 
roles in tumor growth and progression, cancer dissemination, 
and immune escape (12, 15, 36–40). This is exemplified by the 
induction or promotion of
 (i) cell proliferation and survival, for example, by EGF family 
members, interleukin (IL)-6, and TGFβ (41);
 (ii) EMT, cancer cell invasion, and metastasis, in particular, 
through TGFβ (42);
 (iii) stemness by KIT ligand and R-spondins as ligands for 
CD117 (21) and LGR5 (43, 44), respectively.
 (iv) angiogenesis by vascular endothelial growth factor (VEGF), 
basic FGF, and CXCL8/IL-8;
 (v) immune cell migration to the tumor by chemokines of the 
CCL and CXCL families (45);
 (vi) immune cell suppression, for example, by VEGF, IL-6, 
IL-10, LIF, and TGFβ (46); and
 (vii) the accumulation of ascites, mainly though the action of 
VEGF as a vascular permeability factor (47).
Several lines of evidence support the clinical significance of 
these mediators. Thus, evaluation of genomic data has identified 
a number of clinical associations of signaling loops established by 
polypeptide ligands and their receptors in solid tumor tissue of 
advanced ovarian cancer, including TGFβ, PDGF, VEGF, ephrin, 
CXCL12, and CCL chemokines (25). Furthermore, several stud-
ies have demonstrated highly significant associations between the 
ascites levels of various cytokines and the relapse-free survival 
(RFS) or overall survival (OS) of ovarian cancer patients, for 
example, TGFβ, IL-6, IL-10, and LIF (12, 40, 48–52).
Despite their undisputed role within the TME, the reciprocal 
interactions of tumor and host cells via soluble mediators are 
only partially understood. A recent study has addressed this 
issue by determining the transcriptome for tumor cells and 
TAMs from ovarian cancer ascites samples and using these 
data to establish an extensive network of signaling mediators 
and their receptors and thereby the first global overview of the 
origins and targets of cytokines in the TME (Figure  1). This 
study defined multiple signaling pathways between tumor cells 
and TAMs as well as cell type restricted, autocrine mechanisms 
and uncovered new clinically relevant components within this 
signaling network (52).
The multifaceted cooperation of tumor cells and TAMs is 
exemplified by signal transducer and activator of transcription 3 
(STAT3)-inducing cytokines IL-10, IL-6, and LIF, all of which are 
predictive of a poor survival: while the major source and target of 
IL-10 are TAMs, LIF is synthesized by, and acts on, tumor cells, 
whereas IL-6 production and action are not cell type selective 
(52). Both tumor cells and TAMs also contribute to an extensive 
TGFβ-signaling network, consistent with previous findings (42, 
53, 54). Multiple components of these pathways are associated 
with a short RFS, including TGFβ1, TGFβ3, and TGFβR1, the 
former produced most strongly by TAMs (52). Furthermore, 
WNT signaling through frizzled receptors also plays a major 
role, with WNT7A and WNT11 deserving particular attention 
in light of strong associations with a poor survival. The same 
study also revealed a comprehensive network of axon guidance 
molecules, with SEMA5A, SEMA6C, and the ephrin receptor 
gene EPHB2 standing out as strong indicators of a poor RFS. 
On the other hand, the identification of all three components, 
the norrin–frizzled 4–TSPAN12 complex (55), as indicators of 
a longer RFS is particularly intriguing, since this finding points 
to an unexpected role for the frizzled ligand norrin in tumor 
suppression (52).
There is impressive progress in understanding the molecular 
networks regulating TAMs; however, the role of other host 
cells within this signaling network is even less understood, 
including myeloid-derived suppressor cells (MDSCs), different 
types of T cells, NK cells, adipocytes, and fibroblasts, which are 
clearly important constituents of the TME. It is also unknown 
how ascites-associated tumor and host cells differ from their 
counterparts in solid tumor masses. Therefore, the next obvi-
ous step is to extend this work to other cell types of ovarian 
cancer ascites and solid tumor tissue to obtain a complete 
integrated picture of the cytokine signaling network operating 
in the ovarian cancer TME.
THe LiPiD SiGNALiNG NeTwORK OF 
OvARiAN CANCeR ASCiTeS
Molecules generated by the cleavage of phospholipids and pre-
sent in malignant effusions represent another important class of 
soluble cancer-promoting mediators. The first major group of 
lipid mediators highly relevant in the context of ovarian cancer 
ascites is represented by polyunsaturated fatty acids (PUFAs), 
in particular eicosanoids (56–58), including arachidonic acid 
(AA) and its metabolites. These include prostanoids, hydroxy-
eicosatetraenoic acids, and leukotrienes that are derived from 
AA by enzymatic cascades initiated by either cyclooxygenases or 
lipoxygenases. Prostaglandin E2 (PGE2), in particular, is known to 
promote tumor progression as an immune suppressor and trigger 
of angiogenesis (59). The PGE2, PGI2, and LTB4 pathways have 
FiGURe 1 | Continued
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been linked with clinical progression through the PGE2 receptor 
PTGER3 on tumor cells, expression of the PGI2-synthesizing 
enzyme PTGIS by tumor cells and TAMs, as well as release of 
LTB4 into the TME by both cell types (52).
Non-metabolized AA itself is also present in ovarian cancer 
ascites. Its concentrations are inversely linked to RFS (52), 
which is presumably functionally linked to the AA-generating 
phospholipase PLA2G7 (see below). It is possible that these 
FiGURe 1 | Signaling network between tumor cells and tumor-associated macrophages (TAMs) in ovarian cancer ascites. Prominent examples of 
signaling pathways operating between tumor cells (red) and TAMs (blue). Genes for receptors and their cognate ligands are ordered in adjacent blocks on the left 
and right sides, respectively, of each box. The sizes of the filled squares indicate the level of expression determined by RNA-Seq (large: median TPM > 50; 
intermediate: TPM > 10; and small: TPM > 0.3) (52). Open squares indicate cases, where substantial expression (TPM > 3) was observed only in a fraction of 
samples (>10%).
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associations are not (only) due to AA-derived metabolites, since 
AA can act directly on intracellular proteins, including PKC and 
peroxisome proliferator-activated receptors (PPARs) (60–63), in 
particular at the high concentrations of up to 50 µM in ascites 
(52). Linoleic acid, another PUFA present at even higher levels 
in ovarian cancer ascites, did not show any survival associations, 
but was shown to deregulate target genes of PPARβ/δ by acting 
as an endogenous agonistic ligand (63). Intriguingly, several of 
these genes are linked to protumorigenic functions. These include 
ANGPTL4, which is linked to a poor clinical outcome of ovarian 
cancer (63).
The second major group of lipids found in ascites encompasses 
lysophosphatidic acids (LPA), a mixture of lipids with different 
ester- or ether-linked fatty acids in the sn1 position (64–69). 
Extracellular LPA is generated from phospholipids by the con-
secutive action of two enzymes, i.e., secretory phospholipases A2 
and the lysophospholipase D autotaxin (67, 69). LPA production 
is counteracted by lipid phosphatases of the LPPR family (70), 
although LPA degradation seems to play an insignificant role in 
ovarian cancer ascites based on the low expression of LPPR genes 
in both tumor cells and TAMs. TAMs seem to play an essential 
role in phospholipid cleavage as a major source of PLA2G7 and 
FiGURe 2 | Functions of extracellular microvesicles (evs) in ovarian cancer ascites. EVs are released by virtually all cell types of the tumor 
microenvironment and shape cellular functions of both tumor cells and host cells via different pathways. Depicted examples affect major hallmarks of ovarian cancer 
to promote tumor growth and metastasis. A, adipocyte; F, fibroblast; M, mesothelial cell; Mph, macrophage; NK, natural killer cell; T, T cell; Tu, tumor cell.
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autotaxin, the former being associated with a short RFS (52). On 
the other hand, it has been reported that mesothelial cells display 
strong PLA2 activity and may thus significantly contribute to 
LPA production (71). Correlative studies have demonstrated that 
high levels of LPA correlate with poor prognosis (64, 72–75). LPA 
promotes cancer cell survival and multiple steps of the metastatic 
cascade, including adhesion, migration, and invasion of ovarian 
cancer cells (76–87).
LPA interacts with six different G-protein-coupled mem-
brane receptors (LPARs) (69) that are expressed by tumor cells 
and TAMs in a highly cell type-selective fashion (52). This is 
intriguing in view of the fact that different receptors respond 
to different LPA species and trigger distinct, partly overlap-
ping signaling pathways, including cAMP-PKA, PI3K-AKT, 
Ras-MAPK, PLC-Ca2+-PKC, and RHO-ROCK (69) to promote 
cancer cell invasion, chemoresistance, and tumor progression 
(66–68, 71, 88, 89). The role of LPA on TAMs or other host cells 
is unknown. Different LPA species have been detected in ovarian 
cancer ascites (64, 90), but associations of distinct LPAs with 
specific biological features or clinical outcome have not been 
investigated.
eXTRACeLLULAR MiCROveSiCLeS (evs) 
iN OvARiAN CANCeR ASCiTeS
The complex network of cellular interactions and soluble 
factors, which promotes tumor growth, metastasis, immune 
evasion, and drug resistance in ovarian cancer, is also sup-
ported by EVs. EVs are released by tumor cells and normal 
healthy cells and mediate the transfer of proteins, lipids, and 
nucleic acids between malignant and non-malignant cells to 
alter the function and phenotype of the recipient cell. EVs are 
either shed from the cell surface or released as exosomes via 
exocytosis upon generation in multivesicular bodies. Signal 
transmission via EVs adds another level of complexity to the 
cell communication network as EVs simultaneously release 
multiple molecules impinging on signaling pathways in the 
recipient cell. Molecules previously not considered to be 
exchanged between cells, including mRNA and microRNAs 
(miRNAs), are transferred by EVs.
microRNAs are non-coding RNAs that control target genes 
posttranscriptionally. The dysregulation of miRNAs is involved 
in the tumorigenesis of ovarian cancer. Thus, exosomal miRNAs 
isolated from the serum or ascites fluid are probably of clinical 
relevance and may serve as diagnostic markers, as reviewed 
by Nakamura et al. (91). The first study profiling the miRNA 
content of exosomes isolated from patient serum identified 
a disease-specific miRNA signature with exosomal miRNAs 
(miR-21, miR-141, miR-200a, miR-200b, miR-200c, miR-203, 
miR-205, and miR-214) (92). Several follow-up studies demon-
strated that miRNAs not only reflect diagnostic and prognostic 
biomarkers in ovarian cancer but also serve as predictors for 
response to therapy and represent potential therapeutic targets. 
This topic has been covered in depth by a recently published 
review (93).
Even though our knowledge of the molecular composition, 
biological functions, and cellular sources of EVs in ovarian 
cancer is still limited, available evidence suggests that EVs in 
ascites interfere with immune evasion, invasion, and drug resist-
ance (Figure 2). The following paragraphs highlight recent data 
suggesting a role for ascites EVs in ovarian cancer pathogenesis.
Role of Mvs in immune evasion
Several studies investigated the immunomodulating potential of 
EVs derived from different cell types. Strikingly, EVs released by 
dendritic cells (DCs) and B cells reveal antitumor and immune 
stimulatory effects and can provide costimulatory proteins that are 
able to activate T cells when presented with tumor antigens (94). 
Based on these observations, DC-EV-based antitumor vaccina-
tion studies were developed and tested in clinical trials (95–97).
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On the contrary, exosomes secreted from ovarian tumor 
and bystander cells suppress the immune response (9). EVs 
collected from ovarian ascites impaired the cytotoxic activity of 
peripheral lymphocytes and induced apoptosis of lymphocytes 
and DCs. This correlated with the vesicle-associated expression 
of FAS ligand (FAS-L) and TRAIL, both known to be involved 
in apoptosis induction of immune cells. In line with these find-
ings, secreted vesicle-associated FAS-L purified from patient 
ascites could trigger FAS-mediated apoptosis in a T cell line 
(98). These results suggest that vesicle-associated FAS-L coun-
terattacks Fas-bearing immune cells including T cells, thus 
promoting immune evasion to support tumor cell survival. 
Moreover, there is evidence that ovarian ascites EVs can inhibit 
T cell activation by arresting the T cell-signaling cascade (99). 
This was mechanistically attributed to phosphatidylserine 
(PS), which is present on EVs. However, the functional role of 
PS remains to be confirmed since this molecule is required (but 
not sufficient) for the uptake of EVs by recipient cells (100).
Extracellular microvesicles do not only interact with cytotoxic 
lymphocytes but also regulate the activation of MDSCs via vesicle-
associated HSP70, which engages toll-like receptor (TLR) 2 on 
MDSC (101). There is experimental evidence that these mechanisms 
might provide a target for successful immunotherapies. Depletion 
of HSP70-positive EVs and blockade of the HSP70/TLR2 interac-
tion using a specific peptide aptamer diminished the activation 
and number of MDSCs significantly and inhibited tumor progres-
sion in tumor-bearing C57Bl/6 mice. Thus, targeting or interfering 
with EVs holds promise for novel immunotherapies to treat ovar-
ian cancer. However, the development of innovative therapeutic 
concepts requires a more detailed understanding of EV biogen-
esis, molecular composition, and the mechanisms of target cell 
interaction.
Role of evs in invasion
Most studies on ovarian cancer ascites EVs are related to their 
impact on immune evasion, but there is also evidence that EVs 
regulate invasion and metastasis. First, ovarian cancer EVs 
carry molecules that directly regulate tumor cell migration in an 
autocrine or paracrine fashion, including soluble L1 (102), CD24, 
EpCAM (103), and soluble ALCAM (104). Second, membrane 
vesicles from malignant ascites were also found to contain the 
activated proteases: matrix metalloproteinase (MMP)-2, MMP-9, 
uPA (105), and ADAM17/TACE (104). These vesicle-associated 
proteases promote extracellular matrix (ECM) degradation directly 
or through the release of soluble factors from the EVs, which may 
allow tumor cell invasion into the stroma to facilitate metastasis. 
Third, EVs may carry miRNAs, which interfere with invasion and 
migration either positively or negatively. One prominent example 
is the transfer of miR-6126, which targets integrin β1, a key regula-
tor of cancer cell metastasis. The transfer of miR-6126 mimic to 
endothelial cells (ECs) reduced invasion and migration of ovarian 
cancer cells in vitro and tumor growth in vivo (106).
evs and Drug Resistance
The loading of EVs with specific miRNAs and the transfer of 
these miRNAs to recipient cells may also affect drug resistance. 
The vesicle-mediated transfer of miR21 from omental cancer-
associated adipocytes and cancer-associated fibroblasts (CAFs) to 
ovarian cancer cells was recently identified as a pathway causing 
resistance to taxane-based chemotherapy. In the recipient cancer 
cells, miR-21 directly targets APAF1 mRNA, which is indispensa-
ble for the initiation of apoptosis in response to taxanes (32, 107).
Taken together, the vesicle-mediated cross talk between cells 
of the ovarian cancer ascites emerges as a pivotal component 
that establishes a protumorigenic environment promoting—but 
probably not limited to—immune suppression, invasion, and drug 
resistance. It remains a challenge to gain a better understanding of 
the mechanisms regulating cargo sorting into vesicles and their bio-
synthesis to establish links between vesicle-associated signatures, 
effects on signaling pathways, and altered functions in recipient 
cells. This knowledge is a prerequisite to be able to develop new 
therapeutic options for ovarian cancer by interfering with vesicle 
biogenesis, loading with specific cargo or vesicle uptake.
iMPAiRMeNT OF iNNATe iMMUNe CeLLS
The complex immune suppression network that effectively neutral-
izes antitumor immunity is regarded as one of the main reasons for 
disease progression and treatment failure. The activity of immune 
effector cells present within the TME, including CD4 T cells, CD8 
T cells, and NK cells, is inhibited not only directly by tumor cells 
but also by immunesuppressive T regulatory cells (Tregs), imma-
ture DCs, MDSCs, and TAMs (15, 16, 37). The antitumor activity 
of these cells is mediated by the concerted action of a plethora of 
mediators comprising MVs, cytokines (such as IL-10 and TGF-β), 
lipids (for example, PGE2), secreted enzymes (e.g., indolamin-
2,3-dioxygenase and arginase), and membrane-bound ligands 
[including B7-H1 and programmed cells death protein 1 (PD-1)].
Tumor-Associated Macrophages
Tumor-associated macrophages represent the major subpopula-
tion of myeloid cells in ovarian cancer ascites. A hallmark of 
macrophages is their plasticity in response to their micro-
environment (108). Classical activation results in immune 
stimulatory, pro-inflammatory cells, while alternatively activated 
macrophages comprise a wide spectrum of subtypes with func-
tions in tissue repair, angiogenesis, and immune regulation. TAM 
activation is skewed by factors of the TME to adopt a spectrum 
of phenotypes that represent mixed forms of alternatively acti-
vated and pro-inflammatory macrophages (108), which has also 
been clearly demonstrated for TAMs in ovarian cancer ascites 
(12). TAMs do not possess tumoricidal activity, but are rather 
thought to promote immune suppression and various aspects of 
cancer growth and progression, including tumor cell invasion, 
angiogenesis, and metastasis (108) (Figure  3). Consistent with 
these tumor-promoting functions of TAMs, expression of the 
alternative activation marker CD163 in TAMs from malignancy-
associated ascites showed a strong correlation with early relapse 
of serous ovarian carcinoma after first-line therapy (12). Among 
the soluble factors contributing to TAM polarization, tumor 
progression, and a poor clinical outcome, IL-6, IL-10, TGFβ, and 
AA play a prominent role (12, 40, 48–50, 109).
FiGURe 3 | Functions/dysfunctions of tumor-associated macrophages 
(TAMs) in the ovarian cancer tumor microenvironment (TMe) and 
examples of major mediators of these functions. Multiple mediators 
(gray box) in the TME as well as the lack of interferon (IFN)γ determine the 
activation state and function of TAMs. In response to these triggers, TAMs 
produce a plethora of soluble factors impinging on tumor cells and other host 
cells and block the expression of essential antitumor mediators such as 
interleukin (IL)-12.
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As shown in mouse models, normal macrophages can have 
two developmentally different origins. While infiltrating mac-
rophages are derived from blood monocytes produced by the 
bone marrow, resident tissue macrophages, including peritoneal 
macrophages, are of fetal (yolk sac) origin (110–116). Although 
TAMs can be derived from recruited blood monocytes (117–119), 
tissue-resident macrophages can also be a substantial source for 
the generation of TAMs (112, 120–125). A recent study (109) 
has revealed a surprising similarity between TAMs from ovarian 
cancer ascites and resident peritoneal macrophages with respect 
to their global transcriptional profile, the expression of differ-
entiation markers, and their activation state. For example, both 
resident peritoneal macrophages and TAMs are characterized 
by high expression of the alternative activation markers CD163 
and CD206, and both TAMs and peritoneal macrophages express 
genes with essential functions in phagocytosis and antigen 
presentation at similarly high levels. The only clearly discernible 
difference between both cell types was an upregulation of genes 
linked to ECM remodeling in TAMs (109). On the other hand, 
blood monocytes are most likely attracted by chemokines of the 
tumor miroenvironment and therefore consequently contribute 
to the generation of TAMs. However, it remains an unresolved 
issue at present to which extent infiltrating monocytes and 
resident peritoneal macrophages represent the origins of ovarian 
cancer ascites-associated macrophages.
A therapeutically beneficial effect of “re-educated” TAMs has 
been reported for patients with pancreas adenocarcinoma and 
a related mouse model (126), suggesting that TAMs may also 
represent a potential target in ovarian cancer, as both ascites and 
tumor tissue typically show a high density of TAMs. TAMs from 
ovarian cancer ascites can indeed be shifted under experimental 
conditions to trigger a partial cytotoxic activity under experi-
mental conditions (127, 128).1 However, the observations are 
partly contradictory, and activity toward autologous tumor cells 
has not been analyzed. It is, therefore, unclear, whether, and if 
so under which conditions, ovarian cancer TAMs could be (re)
differentiated to macrophages with tumoricidal properties or 
the ability to trigger a cytotoxic response by other immune cells 
under clinically relevant conditions.
Interleukin-12 is a particularly interesting cytokine in the 
context of ovarian cancer due to its immune stimulatory antitu-
mor effects and its inverse associations with disease progression 
(129–131). A hallmark of TAMs in ovarian cancer ascites is their 
defect to release IL-12 in response to inflammatory stimuli, 
which results from a transcriptional block of the IL12B gene 
encoding the p40 subunit (109, 127, 132). Another cytokine with 
beneficial immune stimulatory and antitumor effects in ovarian 
cancer patients is interferon (IFN)γ (133–136) consistent with the 
observation that IFNγ can prevent the skewing of monocyte dif-
ferentiation by ovarian cancer ascites from immune stimulatory 
IL-10lowIL-12high macrophages to TAM-like IL-10highIL-12low cells 
and to abrogate the suppressive effect of ovarian cancer ascites 
on the inducibility by TLRs ligands of IL-12 secretion (127) (see 
text footnote 1). As IL-12 is an essential determinant of a cyto-
toxic immune response, understanding the regulatory network 
impinging on the IL12B gene may be a key to the development of 
efficacious TAM-targeted therapies.
Dysfunction of Other innate immune Cells
Besides macrophages, other myeloid cells and NK cells represent 
the two main subsets of innate immune cells displaying efficient yet 
mechanistically distinct tumor suppressive effects. Consequently, 
both cell types are targeted by tumor immune escape mechanisms. 
One prominent mechanism is the differentiation of myeloid cells 
to MDSCs. These cells comprise a heterogeneous population 
of immature myeloid cells, including immature precursors of 
macrophages, granulocytes, and DCs. MDSCs are capable of 
inhibiting both adaptive and innate immunity via suppression 
of lymphocytes and NK cell activity. Like TAMs and Tregs, 
MDSC significantly impact on patient survival by enhancing 
cancer progression and metastasis (137).
Recruitment of monocytes and their differentiation into 
MDSC or TAMs strongly depends on components within the 
TME. In ovarian cancer, the tumor-associated inflammatory 
mediator PGE2 was shown to attract MDSC into ascites. This 
was dependent on the induced expression of functional CXCR4 
and its ligand CXCL12, facilitating migration of MDSC into the 
1 Adhikary T, Wortmann A, Finkernagel F, Lieber S, Nist A, Stiewe T, et al. Interferon 
signaling in ascites-associated macrophages is associated with a favorable clinical 
outcome in a subgroup of ovarian carcinoma patients. BMC Genomics (2016) 
(submitted).
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ascites (58). Direct or indirect blocking of PGE2 production could 
effectively inhibit MDSC responsiveness, providing a rationale to 
target PGE2 signaling therapeutically (58). Interestingly, tumor-
infiltrating MDSC are the predominant producers of IL-10 and 
also depend on IL-10 to develop their immunosuppressive func-
tion in vivo further, confirming the fundamental role of IL-10 for 
the development and maintenance of a permissive TME (138). 
The molecular mechanisms that regulate the differentiation and 
function of MDSCs in cancer have been partly identified (137); 
however, the mechanisms that recruit MDSCs to the tumor tissue 
and ovarian cancer ascites remain poorly understood.
Another important key component of the innate immune 
system for recognizing and eliminating cancer cells is NK cells. 
The most important cytotoxicity receptors that mediate NK 
cell-dependent immunosurveillance are the CD16 receptor, 
the NKG2D receptor, and the natural cytotoxicity receptors, 
including NKp30. Defects in NK cell function such as impaired 
cytotoxicity/cytokine secretion, aberrant receptor and ligand 
expression, reduced NK cell number, or NK cell anergy are 
reported in malignant diseases and involved in immune escape 
(139). In ovarian cancer ascites, two main pathways inhibiting 
NKG2D (140) and NKp30 (141, 142) activity were described. 
First, ovarian cancer cells release the pro-inflammatory cytokine 
macrophage migration inhibitory factor (MIF), which stimulates 
tumor cell proliferation, migration, and metastasis and promotes 
tumor angiogenesis. MIF targets also NKG2D expression by 
transcriptionally downregulating NKG2D in NK cells to dimin-
ish cytotoxicity toward tumor cells (140). Second, NK cell activity 
in ascites is inhibited due to high levels of soluble B7-H6, one of 
the ligands for the NKp30 receptor. High expression of soluble 
B7-H6 was associated with a diminished NKp30 expression on 
tumor-associated NK cells and impaired NK cell activity (142). 
In line with this observation, lower B7-H6 expression of patients 
correlated with a better OS and reduced metastasis and cancer 
progression (141). Thus, the impaired NK cell functions in the 
ovarian cancer TME may contribute to immune escape, and the 
underlying mechanism should be further investigated.
Interleukin-18-primed NK cells release the chemokines 
CCL3 and CCL4 upon exposure to ovarian cancer cells to attract 
immature immature DCs. The NK-DC cross talk results in 
upregulation of CXCR3 and CCR5 ligands (CXCL9, CXCL10, 
and CCL5) on DCs, which in turn can recruit CD8+ effector 
T cells to the tumor environment (143). Thus, defective NK cell 
activation does not only affect NK-dependent killing of target 
cells but may also impact on the cellular interactions mandatory 
for the development of an antitumor immune response. A better 
understanding of the cross talk among innate immune cells in 
ovarian cancer ascites and the consequences for tumor mainte-
nance and metastasis is one prerequisite for the development of 
elaborated immunotherapies.
iMPAiRMeNT OF THe ANTiTUMOR  
T CeLL ReSPONSe
More than 10 years ago, it was notified that increased accumula-
tion of intratumoral CD3+ T cells [tumor-infiltrating lymphocytes 
(TILs)] in ovarian carcinoma patients delayed the recurrence of 
the disease and was beneficial for survival (144). Other studies 
confirmed that TIL frequency has a prognostic value and may 
be important for establishing immune-based therapy regimens 
(145, 146). The heightened infiltration of TIL was associated with 
increased levels of the cytokine IFNγ, which is a prognostic factor 
for longer survival and has been studied in clinical trials for treating 
ovarian carcinoma (135, 136). Among CD3+ T cells, CD4+ T helper 
1 (Th1) cells and the canonical effector CD8+ T cells, also termed 
cytotoxic T lymphocytes (CTLs), readily produce high amounts 
of IFNγ upon antigen re-encounter (147, 148). Therefore, it was 
conceivable that both CD3+ T cell subpopulations, Th1 cells and 
CTLs, contribute to the antitumor response in ovarian carcinoma 
by maintaining IFNγ production. However, subsequent studies 
revealed that higher frequencies of intraepithelial CD8+ T cells, 
expressing the αE integrin subunit CD103, are associated with a 
better survival prognosis in ovarian cancer, suggesting that CD8+ 
T cells rather than CD4+ lymphocytes contribute to the antitumor 
effects (149–151). Instead, CD4+ T cells dampened the beneficial 
effects of CD8+ T cells, as the survival median of subgroups high 
CD4+ versus CD8+ T cell ratios was significantly shorter.
T Regulatory Cells
The detrimental effect of CD4+ T cells was caused by an immuno-
suppressive subpopulation of T cells expressing the transcription 
factor FOXP3, termed Tregs, but not by FOXP3-negative CD4+ 
T cells (149, 152). Tregs are responsible for the maintenance of 
immune homeostasis by controlling autoimmunity, allergy, and 
inflammation, as well as responses to tumors. There is a high 
diversity within Tregs, dependent on their origin (thymus versus 
periphery), type of immune response they control, and their 
localization (lymphoid versus non-lymphoid tissue). Tumor-
infiltrating Tregs belong to the non-lymphoid subpopulation, 
which differs from Tregs present in the circulation or lymphoid 
organs by the production of the immunesuppressive cytokines 
IL-10 and TGFβ as well as the expression of chemokine receptors 
(e.g., CCR4) and other membrane-associated immune modula-
tors [e.g., cytotoxic T lymphocyte antigen 4 (CTLA4), GITR] 
(153, 154). Several reports described the presence of Tregs within 
ovarian cancer tumor-associated lymphocytes (152, 155, 156), 
and their accumulation correlated inversely with patient survival 
(157, 158). Tumor-associated Tregs suppressed the proliferation 
of, as well as IFNγ and IL-2 production by, CD8+ T cells specific 
for the tumor antigen HER2 and thereby counteracted the protec-
tive effect of tumor-specific effector T cells (158). The ovarian 
cancer environment caused migration of CTLA4+ FOXP3+ 
GITR+ Tregs via the chemokine CCL22, secreted by tumor cells 
and TAMs, and its receptor CCR4, expressed by infiltrating 
Tregs (155, 158) (Figure  4). Accordingly, the application of an 
anti-CCR4 antibody in an experimental model of ovarian carci-
noma blocked Treg migration and enhanced antitumor response 
including increased IFNγ secretion by CD8+ T cells (159). In 
addition, “non-canonical” CD8+FOXP3+ cells (160) seem to be 
involved in ovarian cancer progression. These cells are depend-
ent on TGFβ1 and p38 MAPK signaling (161), but their precise 
function remains unclear.
FiGURe 4 | Ovarian cancer environment and the CD8+ T cell versus  
T regulatory cells (Tregs) balance. Signals provided by cytokines present 
in ovarian carcinoma ascites [interleukin (IL)-6, IL-10] as well as by dendritic 
cells induce exhaustion of CD8+ T cells. Cells coexpressing the inhibitory 
receptors, programmed cells death protein 1 (PD-1) and lymphocyte 
activation gene 3 (LAG3), display the strongest impairment in interferon (IFN)γ 
and TNFα production. Presumably, high antigen concentrations in the ascites 
cause CD8+ T-cell overstimulation leading to CD8+ T cell exhaustion. 
Moreover, the migration of CD8+ T cells into the tumor environment is 
diminished due to impaired expression of the T helper 1-associated 
chemokines CXCL9 and CXCL10. Conversely, the preferential migration of 
immunosuppressive FOXP3+CTLA4+, GITR+CCR4+ Tregs is supported by the 
upregulated chemokine CCL22.
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Deregulation of immune Checkpoints
Besides negative effects of Tregs, there are further factors within 
the ovarian cancer environment that dampen CTL-mediated 
antitumor responses (Figure 4). These include inhibitory path-
ways mediated by CTLA4, PD-1, and lymphocyte activation gene 
3 (LAG3) protein (162–165). On activation via the T cell receptor 
(TCR) and costimulatory molecule CD28, which provides an 
essential signal for growth and survival, T cells upregulate CTLA4. 
CTLA4 is a negative regulator of T cell activity by competing with 
CD28 for the B7-1 and B7-2 ligands on antigen-presenting cells 
(APCs), resulting in cell cycle arrest and attenuation of effector 
function (166). Both, PD-1 and LAG3 are strongly upregulated 
by CD8+ T cells, and their differentiation is skewed toward a 
dysfunctional pathway, termed functional exhaustion (167). This 
state was originally described for CD8+ T cells arising during 
chronic infections upon uncontrolled antigen exposure and is 
characterized by gradual impairment of proliferation and pro-
duction of effector cytokines IFNγ and TNFα (167). However, the 
exhausted CD8+ T cells maintain some effector function, allowing 
them to restrict ongoing viral replication while preventing tissue 
damage (168). This principle might also apply to the ovarian can-
cer environment in which overwhelming antigen exposure and 
an inflammatory milieu may cause CD8+ T cell exhaustion (163, 
164). Nevertheless, the increased numbers of tumor-infiltrating 
CD8+ T cells correlate with a better survival prognosis (144, 149), 
suggesting that TILs maintain their functionality at least partially 
as suggested by increased levels of IFNγ in tumor tissue from 
patients with a favorable clinical outcome (144).
Exhaustion can be reversed by blocking signaling ligands 
expressed on APCs, tumor cells, or tumor-infiltrating immune 
cells (167, 169). Therefore, the main therapeutic focus is cur-
rently placed on the development of antibodies blocking inter-
actions of coinhibitory receptor–ligand pairs (e.g., CTLA4:B7, 
PD-1:PD-L1). These antibodies are termed immune checkpoint 
inhibitors and have demonstrated considerable benefit in clinical 
trials for several cancers including ovarian carcinoma (165, 169, 
170). In a mouse model of ovarian carcinoma, neutralization of 
CTLA4 signals caused regression of growing tumors, however, 
only in an early tumor stage. This was accompanied by activation 
of CD8+ T cells for IFNγ production in vitro (171).
Anti-CTLA4 antibodies (ipilimumab) have been adminis-
tered to ovarian carcinoma patients after vaccination with irra-
diated, autologous tumor cells engineered to secrete GM-CSF. 
This treatment resulted in antitumor effects only in a minority 
of patients, which is in sharp contrast to melanoma (162). The 
histologic analysis revealed a linear relationship between tumor 
necrosis and an increased ratio of intratumoral CD8+ T cells 
to FOXP3+ Tregs (162). This finding suggests that anti-CTLA4 
antibodies could influence not only effector CD8+ T cells but 
also Tregs, which constitutively express CTLA4. Indeed, anti-
CTLA4 monoclonal antibody therapy is associated with deple-
tion of intratumoral FOXP3+CD4+ Tregs and probably with 
elimination of immune checkpoint blockade of effector CTLs 
(172). However, in animal studies, the antitumor activity of anti-
CTLA4 monoclonal antibodies was attributed to the depletion 
of Tregs rather than to the direct activation of effector CTLs 
(173–175). Taken together, these results suggest that the inter-
ference with the CTLA4 pathway, leading to depletion of Tregs 
and probably to activation of effector CD8+ T cells, is involved 
in the control of ovarian carcinoma to some extent. This points 
to the existence of additional mechanisms suppressing CD8+ 
T cell responses, such as the upregulation of PD-1 and LAG3 
expression on TIL (163).
Besides CTLA4, PD-1- and LAG3-expressing CD8+  
T cells specific for tumor-derived antigen NY-EASO-1 were 
also detectable within the ovarian carcinoma infiltrates. 
These molecules were upregulated on CD8+ T cells by IL-6 
and IL-10, present in ovarian carcinoma ascites, as well as by 
tumor-infiltrating DCs. The strongest functional impairment 
in the capability to produce IFNγ and TNFα was detectable 
within the population of CD8+ T cells coexpressing both LAG3 
and PD-1, an effect reversible by the simultaneous blockade 
of these receptors (163). The synergistic suppression of CD8+ 
T cell activity by LAG3 and PD-1 was further evaluated in a 
mouse model of ovarian carcinoma and revealed that physical 
interactions between these molecules contribute to this coop-
erative effect (164). The suppressive effect of ovarian cancer 
ascites also involves dampening of the TCR-induced activation 
of transcription factors NFκB and NFAT, which is crucial for 
T cell activation, presumably resulting from an inhibition of 
signal transduction upstream of PLCγ (176). Consistent with 
the observations that both Tregs and inhibitory molecules 
contribute to the immune suppression in ovarian carcinoma, 
high levels of miR-424(322), which targets the PD-1:PD-L1 and 
CTLA4:B7 pathways, displayed a synergistic antitumor effect 
with chemotherapy by activating CD8+ T cells and reducing 
Treg infiltration in the mouse model (177).
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The blockade of PD-1 by anti-PD-1 antibody (nivolumab) 
in patients with platinum-resistant ovarian cancer showed 
encouraging results (165). In addition to suppressing the activity 
of infiltrating CD8+ T cells, the migration of these cells into the 
TME is prevented by epigenetic suppression of Th1-associated 
cytokines CXCL9 and CXCL10 (178). Thus, epigenetic regula-
tors of Th1-chemokine production caused increased migration 
of CD8+ T cells into the tumor environment associated with 
tumor reduction and improved the antitumor efficacy of immune 
checkpoint blockade in response to anti-PD-L1 antibodies in a 
mouse model (178). These data indicate that regulation of both 
the influx and function of CD8+ T cells in ovarian carcinoma 
need to be taken into account for the development of more effi-
cacious therapies. Taken together, the suppression of the antitu-
mor activity of CD8+ T cells in the ovarian cancer environment 
seems to be evoked by multiple mechanisms, which include (i) 
the inhibition of CD8+ T cell migration, (ii) the induction of 
inhibitory molecules on CD8+ T cells, and (iii) modulated CD8+ 
T cell activity by increased presence of Tregs.
Role of Glucose Metabolism
There is accumulating evidence in experimental models for an 
influence of the TME on the glycolytic metabolism in CD8+  
T cells, which supports proliferation and effector function 
(179). The competition for nutrients between tumor cells 
and T cells has a crucial impact on cancer progression. Thus, 
decreased availability of glucose in the TME suppressed IFNγ 
production and antitumor function of CD8+ T cells along with 
reduced glycolysis (180). Likewise, restriction of glycolysis led 
to insufficient production of phosphoenolpyruvate and defects 
in Ca2+-NFAT signaling, thereby suppressed antitumor CD8+  
T cell function (181). Moreover, elevated extracellular potassium 
concentrations in the tumor environment dampened CD8+ T cell 
antitumor function via impairment of signaling pathways linked 
to metabolism (182). Therefore, elucidating the influence of the 
ovarian cancer environment on CD8+ T cell metabolism might 
extend our understanding on immunosuppression and give new 
insights for therapy strategies.
TUMOR CeLL ADHeSiON AND iNvASiON
Role of Mesothelial Cells and the eCM
The metastatic spread of ovarian cancer cells depends on the inva-
sion into the mesothelium, a mostly squamous epithelium that 
covers all organs within the peritoneal cavity. The mesothelium 
is formed by a single layer of mesothelial cells with an underlying 
basement membrane composed of collagen, fibronectin, and 
laminin. An early event of metastasis involves the attachment of 
ovarian cancer cells present in the ascites to abdominal organs. It 
has been shown that cancer cells attach less firmly to mesothelial 
cells than to the basement membrane (183) and that metastatic 
sites are typically devoid of mesothelial cells (183, 184). It is 
therefore widely believed that mesothelial cells act as a barrier for 
cancer cells and represent the first line of defense against ovarian 
cancer and against other abdominally metastasizing cancers. It is 
well conceivable that ovarian cancer cells attach to ECM at the site 
of pre-existing lesions of the mesothelial cell layer, which might 
occur spontaneously at low frequency or might be fostered by the 
inflammatory environment of the ascites. However, there is no 
experimental evidence for this scenario so far.
Alternatively, ovarian cancer cells can attach directly to meso-
thelial cells, mainly through β1 integrin (185–187) and CD44 
(186, 188, 189). This attachment to mesothelial cells is favored 
by a genetic program of ovarian cancer cells with upregulation 
of mesenchymal genes, including TWIST1 and ZEB1 (190), as 
well as downregulation of epithelial genes like CDH1 encoding 
E-Cadherin (191). The downregulation of E-Cadherin induces 
upregulation of α5β1 integrin, which mediates selective bind-
ing to fibronectin (192), providing a mechanistic basis for the 
enhanced ability to attach to mesothelial cells (191).
During the metastatic process, ovarian cancer cells and 
mesothelial cells mutually influence their behavior in multiple 
ways. Upon contact with mesothelial cells, ovarian cancer cells 
upregulate expression of the MMP-2 to cleave fibronectin and 
vitronectin, with the resulting fragments of fibronectin and 
vitronectin providing enhanced attachment to mesothelial cells 
through the integrins α5β1 and αvβ3 (193). The binding of α5β1 
integrin on cancer cells to fibronectin on mesothelial cells pro-
motes the activation of myosin in the ovarian cancer cells (194). 
As a result, the ovarian cancer cells exert myosin-dependent 
mechanical forces on the mesothelial cell layer to promote the 
disruption of mesothelial intercellular junctions and retraction 
of mesothelial cells leading to gaps within the mesothelial cell 
layer that can be utilized by ovarian cancer cells to invade into the 
submesothelial matrix (184, 194). This process, by which ovarian 
cancer cells impact on the integrity of the mesothelial cell layer, 
has been referred to as “mesothelial clearance” (194). As an alter-
native to invading through gaps in the mesothelial monolayer by 
inducing mesothelial retraction, ovarian cancer cells might gain 
access to the submesothelial tissue by actively killing mesothelial 
cells. Such a mechanism involving the expression of FAS-L on 
cancer cells and FAS on mesothelial cells has been shown for 
colon cancer cells in vitro (195).
In disagreement with the concept that mesothelial cells 
shield the underlying ECM from invasion by ovarian cancer 
cells, prometastatic functions of mesothelial cells have also 
been described. Ovarian cancer cells secrete TGFβ1 to activate 
a TGFβ1/RAC1/SMAD-mediated signaling pathway in meso-
thelial cells that results in secretion of fibronectin by mesothelial 
cells and increased ovarian cancer cell adhesion, invasion, and 
proliferation (196, 197).
After passing through the mesothelial cell layer, ovarian cancer 
cells adhere to the submesothelial basement membrane, locally 
disrupt the basement membrane, and invade into the underlying 
connective tissue (184) (Figure 5). This involves the activation 
of MET in ovarian cancer cells, which is triggered by binding of 
α5β1 integrin on cancer cells to fibronectin (198). Several lines of 
evidence strongly suggest that TAMs contribute to the adhesion 
and invasion of ovarian cancer cells by promoting the remodeling 
of ECM (199). A comparison of the transcriptomes of ovarian 
cancer TAMs to that of peritoneal macrophages from non-cancer 
patients revealed ECM remodeling genes as the main difference 
FiGURe 5 | Ovarian cancer cell adhesion and invasion. Ovarian cancer cells in the ascites adhere to the mesothelium via integrins and CD44. This adhesion is 
further enhanced by matrix metalloproteinase (MMP)-mediated cleavage of fibronectin on mesothelial cells. Ovarian cancer cells then break mesothelial junctions to 
invade through the mesothelial cell layer into the submesothelial extracellular matrix (ECM), where they proliferate and form metastases.
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between these cell populations (109). The clinical significance 
of this observation is supported by a strong correlation of poor 
survival with the expression of these genes in the PRECOG data 
set (109, 200). The molecular basis of the cross talk of ovarian 
cancer cells with cells of their microenvironment (Figure 6), in 
particular with immune cells such as TAMs and T cells in the 
ascites, and its impact on ovarian cancer cell adhesion and inva-
sion are just beginning to be understood. In the following, we will 
summarize data on metastasis-promoting factors in the ascites 
and the molecular signaling pathways induced by them.
Metastasis-Promoting Factors in Ascites
A large body of evidence indicates that LPA, which is frequently 
present in the ascites at high levels, plays a major role in ovarian 
cancer metastasis (see The Lipid Signaling Network of Ovarian 
Cancer Ascites). LPA acts via activation of LPA receptors on 
ovarian cancer cells, the expression of which is upregulated under 
hypoxic conditions that are frequently encountered in the TME 
(77). The effects of LPA on adhesion, migration, and invasion of 
ovarian cancer cells are mediated by multiple intracellular signal-
ing pathways downstream of LPA receptors as described above. 
Mechanistically, LPA increases the expression of β1 integrin on 
ovarian cancer cells with enhanced adhesion to collagen as well 
as of MMPs and promotes the degradation of and invasion into 
the ECM (201). Along the same lines, LPA also induces the down-
regulation of tissue inhibitor of metalloproteinases expression 
(89). Moreover, LPA has been shown to suppress senescence of 
ovarian cancer cells through LPAR2 in the presence of wild-type 
p53 (202) and to induce the expression of VEGF (203).
Vascular endothelial growth factor plays a central role in 
neoangiogenesis, progression, and metastasis of numerous 
types of cancer. In ovarian cancer, VEGF is found in both the 
primary tumor and the ascites at high levels, and VEGF expres-
sion correlates with poor survival (204–206). Accordingly, 
bevacizumab, a monoclonal antibody targeting VEGF, has 
been approved for the treatment of advanced and relapsing 
ovarian cancer and prolongs progression-free survival (207). 
Ovarian cancer cells and TAMs constitute major sources of 
VEGF (52, 208) (Figure  1), but other host cells might also 
contribute to VEGF production (209–211). The expression of 
VEGF is induced by hypoxia (212, 213) and multiple other 
signaling molecules (214). VEGF supports ovarian cancer 
metastasis by acting on both ovarian cancer cells in an auto-
crine or paracrine manner and on other cell types including 
peritoneal ECs and immune cells (see below). The invasion-
promoting effect of VEGF might be mediated, at least in part, 
by an upregulation of MMPS in ovarian cancer cells (215, 216). 
In addition to direct effects on cancer cells, VEGF promotes a 
permissive environment for ovarian cancer cell metastasis by 
acting on peritoneal ECs to promote angiogenesis and vascular 
permeability, leading to the formation of ascites (47). At sites 
of metastatic lesions, VEGF-induced angiogenesis is likely to 
support the growth of larger metastatic nodules. Moreover, 
VEGF might further contribute to ovarian cancer metastasis by 
affecting immune cell functions as there is evidence suggesting 
that VEGF suppresses T cell activation and proliferation (211) 
and that VEGF levels inversely correlate with CD3+CD56+ 
NK-like T cell numbers (217).
FiGURe 6 | Molecular signaling network in the ascites. In addition to cancer cells, the ascites contains several other cell types including tumor-associated 
macrophages (TAMs), cancer-associated adipocytes (CAAs), cancer-associated fibroblasts (CAFs), and T lymphocytes. These cells communicate via multiple 
signaling molecules that promote the metastasis of ovarian cancer cells.
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Role of TAMs and Adipocytes in invasion
Multiple aspects of ovarian cancer biology, including cancer cell 
adhesion and invasion, are under the control of a highly complex 
communication network between different cell types within the 
ovarian cancer TME. For some cytokines, ovarian cancer cells 
or immune cells have been identified as sites of production 
(Figure 1), while for other cytokines, the cell types releasing them 
remain unknown. TAMs represent a central player in the ovarian 
cancer cytokine network to support ovarian cancer cell adhesion 
and invasion (8). They secrete multiple metastasis-promoting 
cytokines including IL-6, IL-10, CCL18, CCL22, TNFα, and 
TGFβ (218). The number of TAMs is positively regulated by 
CCL2/MCP-1, which is released from ovarian cancer cells into 
the ascites (219). IL-6 released by TAMs promotes the adhesion, 
invasion, and proliferation of ovarian cancer cells (51, 220), which 
might be mediated in part by an increase of MMP expression by 
ovarian cancer cells (220). TNFα produced by TAMs also pro-
motes invasion of ovarian cancer cells, the exact mechanism of 
which awaits further clarification (221, 222). Through the release 
of CCL22, TAMs attract Tregs to ovarian cancer cell clusters, 
which in turn suppress cytotoxic T cells (158).
CXCL12/SDF-1 released by an unknown cellular source into 
the ascites acts on cancer cells via CXCR4 (223). The expression 
level of CXCR4 is elevated by binding of ovarian cancer cells to 
ECM via β1 integrin (223). The activation of CXCR4 results in 
the upregulation of the prometastatic cytokines IL-6, CXCL12, 
and TNFα in ovarian cancer cells (8) and increases metastasis 
(224). IL-6 secretion by ovarian cancer cells is also increased by 
platinum-based chemotherapy and promotes the polarization 
of TAMs toward a protumorigenic and chemoresistant pheno-
type (225). Another mediator present in the ascites is the lipid 
sphingosine-1-phosphate (SIP), which stimulates invasion of 
ovarian cancer cells, probably through several different signaling 
pathways downstream of SIP receptors (226–229).
In addition to ovarian cancer and immune cells, adipocytes 
of the omentum are actively involved in cytokine signaling. They 
secrete IL-6, IL-8/CXCL8, CCL2, and adiponectin, which act 
on cancer cells via their respective receptors to support ovarian 
cancer cell metastasis (230). Adipocytes thereby establish a spe-
cific microenvironment with strong growth-promoting effects 
on disseminated ovarian cancer cells. Examples in this context 
are (i) the promotion of tumor cell homing and invasion into 
the omentum by adipocyte-derived IL-8 (230) in cooperation 
with CAFs, (ii) the direct transfer of fatty acids from adipocytes 
to adjacent tumor cells via fatty acid-binding protein 4 for 
energy production (230), and (iii) the activation of the ERBB3 
receptor on metastasizing cancer cells by the mitogenic ligand 
neuregulin 1 (5).
FiGURe 7 | A simplified view of the cell type-specific impact of 
cytokine signaling in the ovarian cancer tumor microenvironment. The 
simultaneous presence of pro- and anti-inflammatory mediators suggests 
that biological outcome depends on both prevalence and interpretation of 
signals. Left: tumor cells respond with persistent activation of the 
transcription factors RELA (p65) and STAT3, leading to promotion of growth, 
progression, and poor clinical outcome. Right: cells of the immune system do 
not receive appropriate combinations of stimuli for pro-inflammatory 
activation and therefore do not activate REL and STAT1. Integration of the 
signaling molecules present in ascites leads to an anti-inflammatory state, at 
least in part through activation of STAT3.
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STAT AND NFκB SiGNALiNG NeTwORKS: 
OPPOSiNG CeLL TYPe-SPeCiFiC 
FUNCTiONS
Similarity of the TMe with the Resolution 
Phase of wound Healing
Besides tumor cells, large populations of Tregs, TAMs, and 
possibly other host cells provide high levels of immunosuppres-
sive mediators, thereby strongly limiting the fraction of cells 
competent to produce the crucial pro-inflammatory cytokines, 
such as IFNγ and IL-12. The influx of potentially cytotoxic T cells, 
monocytes, and NK cells cannot counteract this efficient tumor 
protection scheme: the dominant TME at advanced stages of the 
disease converts their phenotypes toward tumor promotion and 
immune suppression despite the presence of pro-inflammatory 
molecules, including cytokines, lipids, and nitric oxide as well 
as cellular debris and discharged intracellular molecules acting 
as ligands for TLRs (231, 232). This cocktail exerts strong sup-
pressive functions on all types of immune cells, but at the same 
time promotes the protumorigenic properties of cancer cells, 
enabled by cell type-specific signal transduction mechanisms. It 
has been known for a long time that tumors resemble wounds that 
do not heal (233, 234). The final stage of wound healing, termed 
resolution phase, provides effective termination of inflammation. 
Therefore, it is tantalizing to speculate that the TME of advanced 
tumors lock immune cell types in a state resembling a never-
ending resolution phase, while deregulated pro-inflammatory, 
protumorigenic signaling persists in the tumor cells. Consistent 
with this idea is the observation that ovarian cancer TAMs differ 
from normal peritoneal macrophages mainly by the upregulation 
of ECM remodeling genes (109), which is also the hallmark of 
resolution phase (235). Moreover, type I, III, and V collagens are 
major components of the TME, similar to a healing wound (233). 
These collagens are also among the matrix proteins upregulated 
in ovarian cancer TAMs, and their expression shows a striking 
association with poor survival (109).
Cell Type-Specific effects by Mediators of 
the TMe via Differential Signal integration
A vast number of studies attribute the activation states of both 
innate and adaptive immune cells to differential activation of 
JAK/STAT and NFκB signaling. The JAK/STAT network is 
primarily regulated by cytokines that have either pro- or anti-
inflammatory properties (236) and convey intercellular com-
munication. NFκB proteins are effectors of receptors that detect 
either host-elicited or pathogen-derived signals and trigger 
mostly pro-inflammatory responses (237). In cancer cells, the 
very same networks exert mostly protumorigenic functions due 
to differential and constitutive activation of effector molecules 
and regulation of target genes. Thus, in cancer cells, STAT and 
NFκB have been implicated in the stimulation of proliferation, 
suppression of apoptosis, angiogenesis, promotion of invasion, 
and other protumorigenic processes (238). Due to the simultane-
ous presence of a plethora of both pro- and anti-inflammatory 
mediators, the ovarian cancer TME represents an excellent 
model to study how differential signal integration mediates cell 
type-specific biological effects (12, 14–16, 39, 52, 239). The fol-
lowing paragraphs describe the molecular mechanisms that, in 
a simplified view, enable unhindered tumor cell growth, driven 
by constitutive NFκB and STAT3 signaling, and simultaneously 
preclude immune cell activation by preventing pro-inflammatory 
NFκB via STAT3-driven mechanisms (Figure 7).
The iL-12 Paradigm
Regulation of IL-12 expression is a paradigm for the cross talk of 
NFκB and STAT signaling (Figure 8). In humans, macrophages 
exert their tumoricidal activity largely by activating NK cells via 
the secretion of IL-12 and IL-18 (240). Likewise, macrophages 
and other APCs use IL-12 to promote the differentiation of naïve 
T cells to cytotoxic Th1 cells. Occupation of the IL-12 receptor 
on T and NK cells induces STAT4 phosphorylation, leading to 
expression of IFNγ (241), a crucial activator of macrophages and 
class II major histocompatibility complex gene expression and 
thus an essential player in tumor surveillance (242, 243). IL-12 
exerts its pivotal role in antitumor immune surveillance as a 
heterodimer of p35 and p40, encoded by the IL12A and IL12B 
genes, respectively. Expression of IL12B is under stringent tran-
scriptional control and represents the rate-limiting step for IL-12 
production (244).
Transcription of IL12B in macrophages requires the coop-
erative action of two transcription factors activated by different 
signaling pathways, i.e., the NFκB subunit REL and STAT1. While 
NFκB activation is triggered by pro-inflammatory cytokines 
and TLR ligands, STAT1-containing dimers are induced by 
interferons (245). STAT1 acts to orchestrate remodeling of 
promoter-proximal nucleosomes as a prerequisite for activation 
of Il12b transcription by NFκB proteins (246). Thus, the sequen-
tial action of STAT1 and REL in macrophages is crucial for the 
establishment of a cytotoxic immune response that depends on 
IL-12 production by macrophages. This provides for a highly 
FiGURe 8 | Transcriptional circuitry governing the immunesuppressive 
state of macrophages and T cells in the ovarian cancer tumor 
microenvironment (TMe). In tumor-associated macrophages (TAMs), 
interleukin (IL)-10 activates STAT3, which in turn stimulates IL10 transcription. 
Both cooperate to repress IL12B transcription and REL nuclear translocation 
by multiple mechanisms, reinforced by GPCR ligands and nuclear receptor 
(NR) agonists such as glucocorticoids and polyunsaturated fatty acids. In  
T cells, REL plays an ambivalent role by fostering both IL2 and FOXP3 
transcription. The latter depends on the presence of TGFβ and results in 
conversion into a T regulatory cell phenotype. In the ovarian TME or ascites, 
TNFR, toll-like receptor (TLR), T cell receptor (TCR), and CD28-activating 
stimuli are overruled; without long-term pro-inflammatory stimulation, 
upregulation of IFNG transcription is prevented. As a consequence, 
pro-inflammatory signals fail to activate STAT1, induction of IL12B, and 
subsequent sustained production of interferonγ. Dot-shaped nodes denote a 
requirement for both signals (logical AND).
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efficient control mechanism that physiologically safeguards 
against detrimental inflammatory reactions in the absence of 
either activated STAT1 or REL. Tumors exploit this stringent 
regulatory network through signaling mediators that prevent the 
simultaneous activation of both pathways. IL-12 production is 
efficiently suppressed by numerous molecules found in ovarian 
cancer ascites, including IL-10, PS, fatty acid derivatives, and 
G-protein receptor ligands (247–259). The underlying mecha-
nisms include both global and gene-specific suppression of the 
NFκB response in macrophages.
Functions of ReL in T Cells
Apart from its role in APCs, REL is required for the expression of 
IL2 in T and NK cells and thereby necessary for their proliferation, 
survival, and activation (Figure 8). This includes the production 
of IFNγ, thus establishing a positive feedback loop between both 
cell types. Importantly, transcription of both IL12B and IL2 is fully 
dependent on REL; its function cannot be substituted by other 
NFκB proteins (260–262). However, dependent on the microenvi-
ronment, activation of REL in T cells can also dampen the immune 
response, e.g., in the presence of TGFβ, as is the case in ovarian 
cancer ascites. Thus, a number of mouse studies showed that the 
TGFβ-activated SMAD3 transcription factor cooperates with REL 
to induce expression of FOXP3 and that IL-2 contributes to FOXP3 
induction by activating STAT5 (263, 264). As a consequence, 
FOXP3 drives the differentiation of naïve CD4-positive T cells to 
Treg, thereby preventing IFNγ production. These mechanisms are 
physiologically important to enable states of immune privilege or 
tolerance, which ensure that initiation of inflammation is efficiently 
prevented in reproductive organs, brain, and eyes. This regulatory 
network orchestrated by immunosuppressive macrophages and 
Tregs (265) is the blueprint for the immunesuppressive mecha-
nisms invoked in the ovarian cancer TME.
Persistent STAT and NFκB Activation in 
Tumor Cells
In contrast to immune cells, NFκB is constitutively active in 
>50% of ovarian carcinomas and is correlated with poor survival 
(266–268). In fact, inflammatory signaling involving NFκB and 
STATs has been implicated in the genesis of many tumor entities. 
Activation of NFκB in cancer cells is most frequently caused by 
mediators of TME, since mutations of NFκB factors are confined 
to lymphoid malignancies (269). In ovarian cancer ascites, these 
mediators include IL-6, TNFα, as well as TLR and EGF receptor 
ligands (8, 12, 15, 52, 270). Proteins encoded by NFκB target 
genes include anti-apoptotic, growth-promoting, proinvasive, 
proangiogenic and immunesuppressive proteins, exemplified by 
BCLX-L, IL-6, IL-8, VEGF, and PD-1L, which explains its multi-
faceted role in ovarian cancer progression and therapy resistance 
(268, 271). Platinum-based chemotherapy also induces NFκB in 
ovarian carcinoma (272). Strikingly, RELA was found among the 
upregulated proteins in carboplatin-resistant tumors, as well as 
STAT5B (253). STAT5 and STAT3 are frequently hyperactive in 
human cancers, driving apoptotic blockade, invasion, stemness, 
and pro-inflammatory signaling, at least in part through persis-
tent NFκB activation (273–275).
Drugging NFκB and STAT Networks
NFκB signaling impacts both protumorigenic and antitu-
morigenic mechanisms in different cell types; while enabling 
unhindered growth of tumor cells, it is also crucial for innate 
and adaptive immune responses as exemplified by its require-
ment for induction of IL12B. Accordingly, cautionary advice 
has been worded regarding broad pharmacological intervention 
(252, 256). Non-selective targeting, for example, inhibition of 
proteasome activity or bromodomain-mediated acetyl-lysine 
binding, has been tested in clinical studies, but it remains 
unclear whether these compounds have long-lasting benefits. 
Drugs that target factor(s) with protumorigenic roles in both 
tumor and stromal cells may be more promising targets. STAT3 
was proposed as a common factor mediating negative effects 
(274, 275). However, caveats with the development of STAT3 
antagonists are its high homology with STAT1 and its roles 
in barrier function and host defense, and considerable efforts 
dedicated to the development of specific and bioavailable STAT 
antagonists have met with little success (258). To circumvent 
the multifaceted roles of signaling networks, cell type-specific 
signaling will have to be identified and targeted to avoid the 
pitfalls of previous drug development strategies. For example, 
counteracting IL-10 (and other, currently unknown) TME-
mediated immunosuppressive signaling events and thereby 
allowing for STAT1 activation, c-REL translocation, and IL-12 
production might be a promising approach.
16
Worzfeld et al. The Microenvironment of Ovarian Cancer
Frontiers in Oncology | www.frontiersin.org February 2017 | Volume 7 | Article 24
ReFeReNCeS
1. Colombo N, Peiretti M, Parma G, Lapresa M, Mancari R, Carinelli S, et al. 
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical 
Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 
21(Suppl 5):v23–30. doi:10.1093/annonc/mdq244 
2. The Cancer Genome Atlas Research Network. Integrated genomic analyses of 
ovarian carcinoma. Nature (2011) 474(7353):609–15. doi:10.1038/nature10166 
3. Perets R, Wyant GA, Muto KW, Bijron JG, Poole BB, Chin KT, et  al. 
Transformation of the fallopian tube secretory epithelium leads to high-
grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell (2013) 
24(6):751–65. doi:10.1016/j.ccr.2013.10.013 
4. McDaniel AS, Stall JN, Hovelson DH, Cani AK, Liu CJ, Tomlins SA, et al. 
Next-generation sequencing of tubal intraepithelial carcinomas. JAMA Oncol 
(2015) 1(8):1128–32. doi:10.1001/jamaoncol.2015.1618 
5. Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-Raghavan P, 
Miyake T, et  al. Hematogenous metastasis of ovarian cancer: rethinking 
mode of spread. Cancer Cell (2014) 26(1):77–91. doi:10.1016/j.ccr.2014. 
05.002 
6. Lengyel E. Ovarian cancer development and metastasis. Am J Pathol (2010) 
177(3):1053–64. doi:10.2353/ajpath.2010.100105 
7. Steinkamp MP, Winner KK, Davies S, Muller C, Zhang Y, Hoffman RM, 
et  al. Ovarian tumor attachment, invasion, and vascularization reflect 
unique microenvironments in the peritoneum: insights from xenograft and 
mathematical models. Front Oncol (2013) 3:97. doi:10.3389/fonc.2013.00097 
8. Kulbe H, Chakravarty P, Leinster DA, Charles KA, Kwong J, Thompson RG, 
et al. A dynamic inflammatory cytokine network in the human ovarian cancer 
microenvironment. Cancer Res (2012) 72(1):66–75. doi:10.1158/0008-5472.
CAN-11-2178 
9. Peng P, Yan Y, Keng S. Exosomes in the ascites of ovarian cancer patients: 
origin and effects on anti-tumor immunity. Oncol Rep (2011) 25(3):749–62. 
doi:10.3892/or.2010.1119 
10. Latifi A, Luwor RB, Bilandzic M, Nazaretian S, Stenvers K, Pyman J, et al. 
Isolation and characterization of tumor cells from the ascites of ovarian 
cancer patients: molecular phenotype of chemoresistant ovarian tumors. 
PLoS One (2012) 7(10):e46858. doi:10.1371/journal.pone.0046858 
11. Preston CC, Goode EL, Hartmann LC, Kalli KR, Knutson KL. Immunity 
and immune suppression in human ovarian cancer. Immunotherapy (2011) 
3(4):539–56. doi:10.2217/imt.11.20 
12. Reinartz S, Schumann T, Finkernagel F, Wortmann A, Jansen JM, Meissner 
W, et  al. Mixed-polarization phenotype of ascites-associated macrophages 
in human ovarian carcinoma: correlation of CD163 expression, cytokine 
levels and early relapse. Int J Cancer (2014) 134(1):32–42. doi:10.1002/ 
ijc.28335 
13. Takaishi K, Komohara Y, Tashiro H, Ohtake H, Nakagawa T, Katabuchi H, 
et al. Involvement of M2-polarized macrophages in the ascites from advanced 
epithelial ovarian carcinoma in tumor progression via Stat3 activation. 
Cancer Sci (2010) 101(10):2128–36. doi:10.1111/j.1349-7006.2010.01652.x 
14. Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton 
JD, et  al. Rethinking ovarian cancer: recommendations for improv-
ing outcomes. Nat Rev Cancer (2011) 11(10):719–25. doi:10.1038/ 
nrc3144 
15. Ahmed N, Stenvers KL. Getting to know ovarian cancer ascites: opportunities 
for targeted therapy-based translational research. Front Oncol (2013) 3:256. 
doi:10.3389/fonc.2013.00256 
16. Kipps E, Tan DS, Kaye SB. Meeting the challenge of ascites in ovarian cancer: 
new avenues for therapy and research. Nat Rev Cancer (2013) 13(4):273–82. 
doi:10.1038/nrc3432 
17. Lloyd KL, Cree IA, Savage RS. Prediction of resistance to chemotherapy in 
ovarian cancer: a systematic review. BMC Cancer (2015) 15:117. doi:10.1186/
s12885-015-1101-8 
18. Foster R, Buckanovich RJ, Rueda BR. Ovarian cancer stem cells: working 
towards the root of stemness. Cancer Lett (2013) 338(1):147–57. doi:10.1016/ 
j.canlet.2012.10.023 
19. Kwon MJ, Shin YK. Regulation of ovarian cancer stem cells or tumor-ini-
tiating cells. Int J Mol Sci (2013) 14(4):6624–48. doi:10.3390/ijms14046624 
20. Ffrench B, Gasch C, O’Leary JJ, Gallagher MF. Developing ovarian cancer 
stem cell models: laying the pipeline from discovery to clinical intervention. 
Mol Cancer (2014) 13:262. doi:10.1186/1476-4598-13-262 
21. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, et al. Identification 
and characterization of ovarian cancer-initiating cells from primary human 
tumors. Cancer Res (2008) 68(11):4311–20. doi:10.1158/0008-5472.
CAN-08-0364 
22. Di J, Yigit R, Figdor CG, Duiveman-de Boer T, Massuger L, Torensma R. 
Expression compilation of several putative cancer stem cell markers by 
primary ovarian carcinoma. J Cancer Ther (2010) 1:165–73. doi:10.4236/
jct.2010.14026 
23. Meng E, Long B, Sullivan P, McClellan S, Finan MA, Reed E, et al. CD44+/
CD24- ovarian cancer cells demonstrate cancer stem cell properties and 
correlate to survival. Clin Exp Metastasis (2012) 29(8):939–48. doi:10.1007/
s10585-012-9482-4 
24. Kryczek I, Liu S, Roh M, Vatan L, Szeliga W, Wei S, et  al. Expression of 
aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int 
J Cancer (2012) 130(1):29–39. doi:10.1002/ijc.25967 
25. Jaggupilli A, Elkord E. Significance of CD44 and CD24 as cancer stem cell 
markers: an enduring ambiguity. Clin Dev Immunol (2012) 2012:708036. 
doi:10.1155/2012/708036 
26. Zeimet AG, Reimer D, Sopper S, Boesch M, Martowicz A, Roessler J, et al. 
Ovarian cancer stem cells. Neoplasma (2012) 59(6):747–55. doi:10.4149/
neo_2012_094 
27. Martins FC, Santiago I, Trinh A, Xian J, Guo A, Sayal K, et al. Combined 
image and genomic analysis of high-grade serous ovarian cancer reveals 
PTEN loss as a common driver event and prognostic classifier. Genome Biol 
(2014) 15(12):526. doi:10.1186/s13059-014-0526-8 
28. Konecny GE, Wang C, Hamidi H, Winterhoff B, Kalli KR, Dering J, et al. 
Prognostic and therapeutic relevance of molecular subtypes in high-grade 
serous ovarian cancer. J Natl Cancer Inst (2014) 106(10). doi:10.1093/jnci/
dju249 
29. Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday 
S, et al. Whole-genome characterization of chemoresistant ovarian cancer. 
Nature (2015) 521(7553):489–94. doi:10.1038/nature14410 
30. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a 
death-from-cancer signature predicting therapy failure in patients with 
multiple types of cancer. J Clin Invest (2005) 115(6):1503–21. doi:10.1172/
JCI23412 
31. Wang W, Kryczek I, Dostal L, Lin H, Tan L, Zhao L, et al. Effector T cells 
abrogate stroma-mediated chemoresistance in ovarian cancer. Cell (2016) 
165(5):1092–105. doi:10.1016/j.cell.2016.04.009 
32. Au Yeung CL, Co NN, Tsuruga T, Yeung TL, Kwan SY, Leung CS, et  al. 
Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in 
AUTHOR CONTRiBUTiONS
All authors contributed significantly to this review article with a 
focus on specific topics. TW: cancer cell adhesion and invasion; 
ES: EVs and NK cells; MH: T cells; TA: NFκB and STAT signaling 
pathways; UW: clinical aspects; SR: intercellular signaling; RM: 
all other topics, conceptual design, and coordination. All authors 
read and approved the manuscript.
FUNDiNG
Work in the authors’ laboratories is funded by the Deutsche 
Forschungsgemeinschaft (grants WO 1901/2-1 and GRK 2213 to 
TW; PO1408/7-1 to ES; AD474/1-1 to TA; RE 1590/1-1 to SR; 
and Mu601/17-1 to RM), by the Wilhelm-Sander-Stiftung (to SR/
UW), and by Universtätsklinikum Giessen und Marburg (2015 to 
TA/UW; 2016 to MH/SR; 2016 to TW/UW).
17
Worzfeld et al. The Microenvironment of Ovarian Cancer
Frontiers in Oncology | www.frontiersin.org February 2017 | Volume 7 | Article 24
ovarian cancer cells through targeting APAF1. Nat Commun (2016) 7:11150. 
doi:10.1038/ncomms11150 
33. Pogge von Strandmann E, Müller R. Shipping drug resistance: extracellular 
vesicles in ovarian cancer. Trends Mol Med (2016) 22(9):741–3. doi:10.1016/ 
j.molmed.2016.07.006 
34. Liao J, Qian F, Tchabo N, Mhawech-Fauceglia P, Beck A, Qian Z, et  al. 
Ovarian cancer spheroid cells with stem cell-like properties contribute to 
tumor generation, metastasis and chemotherapy resistance through hypox-
ia-resistant metabolism. PLoS One (2014) 9(1):e84941. doi:10.1371/journal.
pone.0084941 
35. Negus RP, Stamp GW, Hadley J, Balkwill FR. Quantitative assessment of the 
leukocyte infiltrate in ovarian cancer and its relationship to the expression of 
C-C chemokines. Am J Pathol (1997) 150(5):1723–34. 
36. Leinster DA, Kulbe H, Everitt G, Thompson R, Perretti M, Gavins FN, et al. 
The peritoneal tumour microenvironment of high-grade serous ovarian 
cancer. J Pathol (2012) 227(2):136–45. doi:10.1002/path.4002 
37. Thibault B, Castells M, Delord JP, Couderc B. Ovarian cancer microenviron-
ment: implications for cancer dissemination and chem oresis tance acquisition. 
Cancer Metastasis Rev (2013) 33(1):17–39. doi:10.1007/s10555-013-9456-2 
38. Mills GB, May C, Hill M, Campbell S, Shaw P, Marks A. Ascitic fluid from 
human ovarian cancer patients contains growth factors necessary for 
intraperitoneal growth of human ovarian adenocarcinoma cells. J Clin Invest 
(1990) 86(3):851–5. doi:10.1172/JCI114784 
39. Matte I, Lane D, Laplante C, Rancourt C, Piche A. Profiling of cytokines 
in human epithelial ovarian cancer ascites. Am J Cancer Res (2012) 2(5): 
566–80. 
40. Lane D, Matte I, Rancourt C, Piche A. Prognostic significance of IL-6 and 
IL-8 ascites levels in ovarian cancer patients. BMC Cancer (2011) 11:210. 
doi:10.1186/1471-2407-11-210 
41. Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflam-
mation and cancer. Eur J Cancer (2005) 41(16):2502–12. doi:10.1016/ 
j.ejca.2005.08.016 
42. Marchini S, Fruscio R, Clivio L, Beltrame L, Porcu L, Fuso Nerini I, et al. 
Resistance to platinum-based chemotherapy is associated with epithelial to 
mesenchymal transition in epithelial ovarian cancer. Eur J Cancer (2013) 
49(2):520–30. doi:10.1016/j.ejca.2012.06.026 
43. Flesken-Nikitin A, Hwang CI, Cheng CY, Michurina TV, Enikolopov G, 
Nikitin AY. Ovarian surface epithelium at the junction area contains a 
cancer-prone stem cell niche. Nature (2013) 495(7440):241–5. doi:10.1038/
nature11979 
44. de Lau W, Peng WC, Gros P, Clevers H. The R-spondin/Lgr5/Rnf43 module: 
regulator of Wnt signal strength. Genes Dev (2014) 28(4):305–16. doi:10.1101/
gad.235473.113 
45. Mishra P, Banerjee D, Ben-Baruch A. Chemokines at the crossroads of 
tumor-fibroblast interactions that promote malignancy. J Leukoc Biol (2011) 
89(1):31–9. doi:10.1189/jlb.0310182 
46. Duluc D, Delneste Y, Tan F, Moles MP, Grimaud L, Lenoir J, et  al. 
Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte 
differentiation into tumor-associated macrophage-like cells. Blood (2007) 
110(13):4319–30. doi:10.1182/blood-2007-02-072587 
47. Byrne AT, Ross L, Holash J, Nakanishi M, Hu L, Hofmann JI, et al. Vascular 
endothelial growth factor-trap decreases tumor burden, inhibits ascites, 
and causes dramatic vascular remodeling in an ovarian cancer model. Clin 
Cancer Res (2003) 9(15):5721–8. 
48. Scambia G, Testa U, Benedetti Panici P, Foti E, Martucci R, Gadducci A, et al. 
Prognostic significance of interleukin 6 serum levels in patients with ovarian 
cancer. Br J Cancer (1995) 71(2):354–6. 
49. Lo CW, Chen MW, Hsiao M, Wang S, Chen CA, Hsiao SM, et al. IL-6 trans- 
signaling in formation and progression of malignant ascites in ovarian cancer. 
Cancer Res (2011) 71(2):424–34. doi:10.1158/0008-5472.CAN-10-1496 
50. Yanaihara N, Anglesio MS, Ochiai K, Hirata Y, Saito M, Nagata C, et  al. 
Cytokine gene expression signature in ovarian clear cell carcinoma. Int 
J Oncol (2012) 41(3):1094–100. doi:10.3892/ijo.2012.1533 
51. Isobe A, Sawada K, Kinose Y, Ohyagi-Hara C, Nakatsuka E, Makino H, et al. 
Interleukin 6 receptor is an independent prognostic factor and a potential 
therapeutic target of ovarian cancer. PLoS One (2015) 10(2):e0118080. 
doi:10.1371/journal.pone.0118080 
52. Reinartz S, Finkernagel F, Adhikary T, Rohnalter V, Schumann T, Schober Y, 
et al. A transcriptome-based global map of signaling pathways in the ovarian 
cancer microenvironment associated with clinical outcome. Genome Biol 
(2016) 17(1):108. doi:10.1186/s13059-016-0956-6 
53. Riester M, Wei W, Waldron L, Culhane AC, Trippa L, Oliva E, et  al. Risk 
prediction for late-stage ovarian cancer by meta-analysis of 1525 patient 
samples. J Natl Cancer Inst (2014) 106(5). doi:10.1093/jnci/dju048 
54. Eng KH, Ruggeri C. Connecting prognostic ligand receptor signaling loops 
in advanced ovarian cancer. PLoS One (2014) 9(9):e107193. doi:10.1371/
journal.pone.0107193 
55. Junge HJ, Yang S, Burton JB, Paes K, Shu X, French DM, et  al. TSPAN12 
regulates retinal vascular development by promoting Norrin- but not 
Wnt-induced FZD4/beta-catenin signaling. Cell (2009) 139(2):299–311. 
doi:10.1016/j.cell.2009.07.048 
56. Punnonen R, Seppala E, Punnonen K, Heinonen PK. Fatty acid composition 
and arachidonic acid metabolites in ascitic fluid of patients with ovarian 
cancer. Prostaglandins Leukot Med (1986) 22(2):153–8. 
57. Wymann MP, Schneiter R. Lipid signalling in disease. Nat Rev Mol Cell Biol 
(2008) 9(2):162–76. doi:10.1038/nrm2335 
58. Obermajer N, Muthuswamy R, Odunsi K, Edwards RP, Kalinski P. PGE(2)-
induced CXCL12 production and CXCR4 expression controls the accumu-
lation of human MDSCs in ovarian cancer environment. Cancer Res (2011) 
71(24):7463–70. doi:10.1158/0008-5472.CAN-11-2449 
59. Kalinski P. Regulation of immune responses by prostaglandin E2. J Immunol 
(2012) 188(1):21–8. doi:10.4049/jimmunol.1101029 
60. Khan WA, Blobe GC, Hannun YA. Arachidonic acid and free fatty acids 
as second messengers and the role of protein kinase C. Cell Signal (1995) 
7(3):171–84. 
61. Xu HE, Lambert MH, Montana VG, Parks DJ, Blanchard SG, Brown PJ, et al. 
Molecular recognition of fatty acids by peroxisome proliferator-activated 
receptors. Mol Cell (1999) 3(3):397–403. 
62. O’Flaherty JT, Chadwell BA, Kearns MW, Sergeant S, Daniel LW. Protein 
kinases C translocation responses to low concentrations of arachidonic acid. 
J Biol Chem (2001) 276(27):24743–50. doi:10.1074/jbc.M101093200 
63. Schumann T, Adhikary T, Wortmann A, Finkernagel F, Lieber S, Schnitzer 
E, et  al. Deregulation of PPARβ/d target genes in tumor-associated mac-
rophages by fatty acid ligands in the ovarian cancer microenvironment. 
Oncotarget (2015) 6(15):13416–33. doi:10.18632/oncotarget.3826 
64. Xu Y, Gaudette DC, Boynton JD, Frankel A, Fang XJ, Sharma A, et  al. 
Characterization of an ovarian cancer activating factor in ascites from 
ovarian cancer patients. Clin Cancer Res (1995) 1(10):1223–32. 
65. Westermann AM, Havik E, Postma FR, Beijnen JH, Dalesio O, Moolenaar 
WH, et  al. Malignant effusions contain lysophosphatidic acid (LPA)-like 
activity. Ann Oncol (1998) 9(4):437–42. 
66. Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in 
cancer. Nat Rev Cancer (2003) 3(8):582–91. doi:10.1038/nrc1143 
67. Houben AJ, Moolenaar WH. Autotaxin and LPA receptor signaling in 
cancer. Cancer Metastasis Rev (2011) 30(3–4):557–65. doi:10.1007/s10555- 
011-9319-7 
68. Tsujiuchi T, Araki M, Hirane M, Dong Y, Fukushima N. Lysophosphatidic 
acid receptors in cancer pathobiology. Histol Histopathol (2013) 29(3): 
313–21. doi:10.14670/HH-29.313 
69. Chun J, Hla T, Spiegel S, Moolenaar W. Lysophospholipid Receptors: Signaling 
and Biochemistry. Hoboken, NJ: John Wiley & Sons, Inc (2013).
70. Tanyi JL, Hasegawa Y, Lapushin R, Morris AJ, Wolf JK, Berchuck A, et al. 
Role of decreased levels of lipid phosphate phosphatase-1 in accumulation 
of lysophosphatidic acid in ovarian cancer. Clin Cancer Res (2003) 9(10 Pt 
1):3534–45. 
71. Ren J, Xiao YJ, Singh LS, Zhao X, Zhao Z, Feng L, et al. Lysophosphatidic 
acid is constitutively produced by human peritoneal mesothelial cells 
and enhances adhesion, migration, and invasion of ovarian cancer 
cells. Cancer Res (2006) 66(6):3006–14. doi:10.1158/0008-5472.CAN- 
05-1292 
72. Sutphen R, Xu Y, Wilbanks GD, Fiorica J, Grendys EC Jr, LaPolla JP, et al. 
Lysophospholipids are potential biomarkers of ovarian cancer. Cancer 
Epidemiol Biomarkers Prev (2004) 13(7):1185–91. 
73. Xiao YJ, Schwartz B, Washington M, Kennedy A, Webster K, Belinson J, et al. 
Electrospray ionization mass spectrometry analysis of lysophospholipids in 
human ascitic fluids: comparison of the lysophospholipid contents in malig-
nant vs nonmalignant ascitic fluids. Anal Biochem (2001) 290(2):302–13. 
doi:10.1006/abio.2001.5000 
18
Worzfeld et al. The Microenvironment of Ovarian Cancer
Frontiers in Oncology | www.frontiersin.org February 2017 | Volume 7 | Article 24
74. Xu Y, Fang XJ, Casey G, Mills GB. Lysophospholipids activate ovarian and 
breast cancer cells. Biochem J (1995) 309(Pt 3):933–40. 
75. Xu Y, Shen Z, Wiper DW, Wu M, Morton RE, Elson P, et al. Lysophosphatidic 
acid as a potential biomarker for ovarian and other gynecologic cancers. 
JAMA (1998) 280(8):719–23. 
76. Fang X, Yu S, Bast RC, Liu S, Xu HJ, Hu SX, et al. Mechanisms for lysophos-
phatidic acid-induced cytokine production in ovarian cancer cells. J Biol 
Chem (2004) 279(10):9653–61. doi:10.1074/jbc.M306662200 
77. Kim KS, Sengupta S, Berk M, Kwak YG, Escobar PF, Belinson J, et al. Hypoxia 
enhances lysophosphatidic acid responsiveness in ovarian cancer cells and 
lysophosphatidic acid induces ovarian tumor metastasis in vivo. Cancer Res 
(2006) 66(16):7983–90. doi:10.1158/0008-5472.CAN-05-4381 
78. Kim EK, Yun SJ, Do KH, Kim MS, Cho M, Suh DS, et al. Lysophosphatidic 
acid induces cell migration through the selective activation of Akt1. Exp 
Mol Med (2008) 40(4):445–52. doi:10.3858/emm.2008.40.4.445 
79. Gaetano CG, Samadi N, Tomsig JL, Macdonald TL, Lynch KR, Brindley 
DN. Inhibition of autotaxin production or activity blocks lysophosphati-
dylcholine-induced migration of human breast cancer and melanoma cells. 
Mol Carcinog (2009) 48(9):801–9. doi:10.1002/mc.20524 
80. Song Y, Wu J, Oyesanya RA, Lee Z, Mukherjee A, Fang X. Sp-1 and 
c-Myc mediate lysophosphatidic acid-induced expression of vascular 
endothelial growth factor in ovarian cancer cells via a hypoxia-inducible 
factor-1-independent mechanism. Clin Cancer Res (2009) 15(2):492–501. 
doi:10.1158/1078-0432.CCR-08-1945 
81. Seo JH, Jeong KJ, Oh WJ, Sul HJ, Sohn JS, Kim YK, et al. Lysophosphatidic 
acid induces STAT3 phosphorylation and ovarian cancer cell motility: 
their inhibition by curcumin. Cancer Lett (2010) 288(1):50–6. doi:10.1016/ 
j.canlet.2009.06.023 
82. Vidot S, Witham J, Agarwal R, Greenhough S, Bamrah HS, Tigyi GJ, et al. 
Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells. 
Cell Signal (2010) 22(6):926–35. doi:10.1016/j.cellsig.2010.01.017 
83. Kim EK, Park JM, Lim S, Choi JW, Kim HS, Seok H, et al. Activation of AMP-
activated protein kinase is essential for lysophosphatidic acid-induced cell 
migration in ovarian cancer cells. J Biol Chem (2011) 286(27):24036–45. 
doi:10.1074/jbc.M110.209908 
84. Wu J, Mukherjee A, Lebman DA, Fang X. Lysophosphatidic acid-induced 
p21Waf1 expression mediates the cytostatic response of breast and 
ovarian cancer cells to TGFbeta. Mol Cancer Res (2011) 9(11):1562–70. 
doi:10.1158/1541-7786.MCR-11-0340 
85. Cai H, Xu Y. The role of LPA and YAP signaling in long-term migration 
of human ovarian cancer cells. Cell Commun Signal (2013) 11(1):31. 
doi:10.1186/1478-811X-11-31 
86. Burkhalter RJ, Westfall SD, Liu Y, Stack MS. Lysophosphatidic acid 
initiates epithelial to mesenchymal transition and induces beta-catenin- 
mediated transcription in epithelial ovarian carcinoma. J Biol Chem (2015) 
290(36):22143–54. doi:10.1074/jbc.M115.641092 
87. Nakayama J, Raines TA, Lynch KR, Slack-Davis JK. Decreased peritoneal 
ovarian cancer growth in mice lacking expression of lipid phosphate 
phosphohydrolase 1. PLoS One (2015) 10(3):e0120071. doi:10.1371/journal.
pone.0120071 
88. Brindley DN, Lin FT, Tigyi GJ. Role of the autotaxin-lysophosphatidate axis 
in cancer resistance to chemotherapy and radiotherapy. Biochim Biophys 
Acta (2013) 1831(1):74–85. doi:10.1016/j.bbalip.2012.08.015 
89. Sengupta S, Kim KS, Berk MP, Oates R, Escobar P, Belinson J, et  al. 
Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, 
which are negatively involved in lysophosphatidic acid-induced cell inva-
sion. Oncogene (2007) 26(20):2894–901. doi:10.1038/sj.onc.1210093 
90. Lu J, Xiao YJ, Baudhuin LM, Hong G, Xu Y. Role of ether-linked lysophos-
phatidic acids in ovarian cancer cells. J Lipid Res (2002) 43(3):463–76. 
91. Nakamura K, Sawada K, Yoshimura A, Kinose Y, Nakatsuka E, Kimura T. 
Clinical relevance of circulating cell-free microRNAs in ovarian cancer. Mol 
Cancer (2016) 15(1):48. doi:10.1186/s12943-016-0536-0 
92. Taylor DD, Gercel-Taylor C. Tumour-derived exosomes and their role in 
cancer-associated T-cell signalling defects. Br J Cancer (2005) 92(2):305–11. 
doi:10.1038/sj.bjc.6602316 
93. Mahdian-Shakib A, Dorostkar R, Tat M, Hashemzadeh MS, Saidi N. 
Differential role of microRNAs in prognosis, diagnosis, and therapy of 
ovarian cancer. Biomed Pharmacother (2016) 84:592–600. doi:10.1016/ 
j.biopha.2016.09.087 
94. Robbins PD, Morelli AE. Regulation of immune responses by extracellular 
vesicles. Nat Rev Immunol (2014) 14(3):195–208. doi:10.1038/nri3622 
95. Besse B, Charrier M, Lapierre V, Dansin E, Lantz O, Planchard D, et  al. 
Dendritic cell-derived exosomes as maintenance immunotherapy after first 
line chemotherapy in NSCLC. Oncoimmunology (2016) 5(4):e1071008. 
doi:10.1080/2162402X.2015.1071008 
96. Escudier B, Dorval T, Chaput N, Andre F, Caby MP, Novault S, et  al. 
Vaccination of metastatic melanoma patients with autologous dendritic cell 
(DC) derived-exosomes: results of thefirst phase I clinical trial. J Transl Med 
(2005) 3(1):10. doi:10.1186/1479-5876-3-10 
97. Morse MA, Garst J, Osada T, Khan S, Hobeika A, Clay TM, et al. A phase I 
study of dexosome immunotherapy in patients with advanced non-small cell 
lung cancer. J Transl Med (2005) 3(1):9. doi:10.1186/1479-5876-3-9 
98. Abrahams VM, Straszewski SL, Kamsteeg M, Hanczaruk B, Schwartz PE, 
Rutherford TJ, et  al. Epithelial ovarian cancer cells secrete functional Fas 
ligand. Cancer Res (2003) 63(17):5573–81. 
99. Kelleher RJ Jr, Balu-Iyer S, Loyall J, Sacca AJ, Shenoy GN, Peng P, et  al. 
Extracellular vesicles present in human ovarian tumor microenvironments 
induce a phosphatidylserine-dependent arrest in the T-cell signaling cas-
cade. Cancer Immunol Res (2015) 3(11):1269–78. doi:10.1158/2326-6066.
CIR-15-0086 
100. Keller S, Konig AK, Marme F, Runz S, Wolterink S, Koensgen D, et al. Systemic 
presence and tumor-growth promoting effect of ovarian carcinoma released 
exosomes. Cancer Lett (2009) 278(1):73–81. doi:10.1016/j.canlet.2008.12.028 
101. Gobbo J, Marcion G, Cordonnier M, Dias AM, Pernet N, Hammann A, 
et  al. Restoring anticancer immune response by targeting tumor-derived 
exosomes with a HSP70 peptide aptamer. J Natl Cancer Inst (2016) 108(3). 
doi:10.1093/jnci/djv330 
102. Gutwein P, Stoeck A, Riedle S, Gast D, Runz S, Condon TP, et al. Cleavage 
of L1 in exosomes and apoptotic membrane vesicles released from ovarian 
carcinoma cells. Clin Cancer Res (2005) 11(7):2492–501. doi:10.1158/1078-
0432.CCR-04-1688 
103. Runz S, Keller S, Rupp C, Stoeck A, Issa Y, Koensgen D, et  al. Malignant 
ascites-derived exosomes of ovarian carcinoma patients contain CD24 
and EpCAM. Gynecol Oncol (2007) 107(3):563–71. doi:10.1016/j.ygyno. 
2007.08.064 
104. Carbotti G, Orengo AM, Mezzanzanica D, Bagnoli M, Brizzolara A, 
Emionite L, et  al. Activated leukocyte cell adhesion molecule soluble 
form: a potential biomarker of epithelial ovarian cancer is increased 
in type II tumors. Int J Cancer (2013) 132(11):2597–605. doi:10.1002/
ijc.27948 
105. Graves LE, Ariztia EV, Navari JR, Matzel HJ, Stack MS, Fishman DA. 
Proinvasive properties of ovarian cancer ascites-derived membrane vesicles. 
Cancer Res (2004) 64(19):7045–9. doi:10.1158/0008-5472.CAN-04-1800 
106. Kanlikilicer P, Saber M, Bayraktar R, Mitra R, Ivan C, Aslan B, et al. Ubiquitous 
release of exosomal tumor suppressor miR-6126 from ovarian cancer cells. 
Cancer Res (2016) 76(24):7194–207. doi:10.1158/0008-5472.CAN-16-0714 
107. Strandmann EP, Muller R. Shipping drug resistance: extracellular vesicles 
in ovarian cancer. Trends Mol Med (2016) 22(9):741–3. doi:10.1016/ 
j.molmed.2016.07.006 
108. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to 
therapy. Immunity (2014) 41(1):49–61. doi:10.1016/j.immuni.2014.06.010 
109. Finkernagel F, Reinartz S, Lieber S, Adhikary T, Wortmann A, Hoffmann 
N, et  al. The transcriptional signature of human ovarian carcinoma mac-
rophages is associated with extracellular matrix reorganization. Oncotarget 
(2016) 17:75339–52. doi:10.18632/oncotarget.12180 
110. Schulz C, Gomez Perdiguero E, Chorro L, Szabo-Rogers H, Cagnard 
N, Kierdorf K, et  al. A lineage of myeloid cells independent of Myb and 
hematopoietic stem cells. Science (2012) 336(6077):86–90. doi:10.1126/
science.1219179 
111. Rosas M, Davies LC, Giles PJ, Liao CT, Kharfan B, Stone TC, et  al. The 
transcription factor Gata6 links tissue macrophage phenotype and pro-
liferative renewal. Science (2014) 344(6184):645–8. doi:10.1126/science. 
1251414 
112. Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, 
homeostasis and disease. Nature (2013) 496(7446):445–55. doi:10.1038/
nature12034 
113. Davies LC, Jenkins SJ, Allen JE, Taylor PR. Tissue-resident macrophages. 
Nat Immunol (2013) 14(10):986–95. doi:10.1038/ni.2705 
19
Worzfeld et al. The Microenvironment of Ovarian Cancer
Frontiers in Oncology | www.frontiersin.org February 2017 | Volume 7 | Article 24
114. Davies LC, Taylor PR. Tissue-resident macrophages: then and now. 
Immunology (2015) 144(4):541–8. doi:10.1111/imm.12451 
115. Cassado Ados A, D’Imperio Lima MR, Bortoluci KR. Revisiting mouse 
peritoneal macrophages: heterogeneity, development, and function. Front 
Immunol (2015) 6:225. doi:10.3389/fimmu.2015.00225 
116. Ghosn EE, Cassado AA, Govoni GR, Fukuhara T, Yang Y, Monack DM, et al. 
Two physically, functionally, and developmentally distinct peritoneal macro-
phage subsets. Proc Natl Acad Sci U S A (2010) 107(6):2568–73. doi:10.1073/
pnas.0915000107 
117. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polariza-
tion: tumor-associated macrophages as a paradigm for polarized M2 mono-
nuclear phagocytes. Trends Immunol (2002) 23(11):549–55. doi:10.1016/
S1471-4906(02)02302-5 
118. Pollard JW. Tumour-educated macrophages promote tumour progression 
and metastasis. Nat Rev Cancer (2004) 4(1):71–8. doi:10.1038/nrc1256 
119. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation 
of myeloid cells by tumours. Nat Rev Immunol (2012) 12(4):253–68. 
doi:10.1038/nri3175 
120. Williams CB, Yeh ES, Soloff AC. Tumor-associated macrophages: unwitting 
accomplices in breast cancer malignancy. NPJ Breast Cancer (2016) 2. 
doi:10.1038/npjbcancer.2015.25 
121. Campbell MJ, Tonlaar NY, Garwood ER, Huo D, Moore DH, Khramtsov 
AI, et  al. Proliferating macrophages associated with high grade, hormone 
receptor negative breast cancer and poor clinical outcome. Breast Cancer Res 
Treat (2011) 128(3):703–11. doi:10.1007/s10549-010-1154-y 
122. Tymoszuk P, Evens H, Marzola V, Wachowicz K, Wasmer MH, Datta S, 
et al. In situ proliferation contributes to accumulation of tumor-associated 
macrophages in spontaneous mammary tumors. Eur J Immunol (2014) 
44(8):2247–62. doi:10.1002/eji.201344304 
123. Liu Y, Cao X. The origin and function of tumor-associated macrophages. Cell 
Mol Immunol (2015) 12(1):1–4. doi:10.1038/cmi.2014.83 
124. Pucci F, Venneri MA, Biziato D, Nonis A, Moi D, Sica A, et al. A distinguish-
ing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, 
blood “resident” monocytes, and embryonic macrophages suggests common 
functions and developmental relationships. Blood (2009) 114(4):901–14. 
doi:10.1182/blood-2009-01-200931 
125. Franklin RA, Liao W, Sarkar A, Kim MV, Bivona MR, Liu K, et al. The cel-
lular and molecular origin of tumor-associated macrophages. Science (2014) 
344(6186):921–5. doi:10.1126/science.1252510 
126. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun 
W, et al. CD40 agonists alter tumor stroma and show efficacy against pan-
creatic carcinoma in mice and humans. Science (2011) 331(6024):1612–6. 
doi:10.1126/science.1198443 
127. Duluc D, Corvaisier M, Blanchard S, Catala L, Descamps P, Gamelin E, et al. 
Interferon-gamma reverses the immunosuppressive and protumoral proper-
ties and prevents the generation of human tumor-associated macrophages. 
Int J Cancer (2009) 125(2):367–73. doi:10.1002/ijc.24401 
128. Bellora F, Castriconi R, Dondero A, Pessino A, Nencioni A, Liggieri G, 
et  al. TLR activation of tumor-associated macrophages from ovarian 
cancer patients triggers cytolytic activity of NK cells. Eur J Immunol (2014) 
44(6):1814–22. doi:10.1002/eji.201344130 
129. Kusuda T, Shigemasa K, Arihiro K, Fujii T, Nagai N, Ohama K. Relative 
expression levels of Th1 and Th2 cytokine mRNA are independent prognostic 
factors in patients with ovarian cancer. Oncol Rep (2005) 13(6):1153–8.
130. Koneru M, Purdon TJ, Spriggs D, Koneru S, Brentjens RJ. IL-12 secreting 
tumor-targeted chimeric antigen receptor T cells eradicate ovarian 
tumors in  vivo. Oncoimmunology (2015) 4(3):e994446. doi:10.4161/21624
02X.2014.994446 
131. Cohen CA, Shea AA, Heffron CL, Schmelz EM, Roberts PC. Interleukin-12 
immunomodulation delays the onset of lethal peritoneal disease of 
ovarian cancer. J Interferon Cytokine Res (2016) 36(1):62–73. doi:10.1089/
jir.2015.0049 
132. Saccani A, Schioppa T, Porta C, Biswas SK, Nebuloni M, Vago L, et al. p50 
nuclear factor-kappaB overexpression in tumor-associated macrophages 
inhibits M1 inflammatory responses and antitumor resistance. Cancer Res 
(2006) 66(23):11432–40. doi:10.1158/0008-5472.CAN-06-1867 
133. Allavena P, Peccatori F, Maggioni D, Erroi A, Sironi M, Colombo N, et al. 
Intraperitoneal recombinant gamma-interferon in patients with recurrent 
ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine produc-
tion in tumor-associated effectors and of major histocompatibility antigen 
expression on tumor cells. Cancer Res (1990) 50(22):7318–23. 
134. Pujade-Lauraine E, Guastalla JP, Colombo N, Devillier P, Francois E, 
Fumoleau P, et al. Intraperitoneal recombinant interferon gamma in ovarian 
cancer patients with residual disease at second-look laparotomy. J Clin Oncol 
(1996) 14(2):343–50. 
135. Windbichler GH, Hausmaninger H, Stummvoll W, Graf AH, Kainz C, 
Lahodny J, et al. Interferon-gamma in the first-line therapy of ovarian cancer: 
a randomized phase III trial. Br J Cancer (2000) 82(6):1138–44. doi:10.1054/
bjoc.1999.1053 
136. Marth C, Windbichler GH, Hausmaninger H, Petru E, Estermann K, Pelzer 
A, et al. Interferon-gamma in combination with carboplatin and paclitaxel as 
a safe and effective first-line treatment option for advanced ovarian cancer: 
results of a phase I/II study. Int J Gynecol Cancer (2006) 16(4):1522–8. 
doi:10.1111/j.1525-1438.2006.00622.x 
137. Condamine T, Ramachandran I, Youn JI, Gabrilovich DI. Regulation of 
tumor metastasis by myeloid-derived suppressor cells. Annu Rev Med (2015) 
66:97–110. doi:10.1146/annurev-med-051013-052304 
138. Hart KM, Byrne KT, Molloy MJ, Usherwood EM, Berwin B. IL-10 immu-
nomodulation of myeloid cells regulates a murine model of ovarian cancer. 
Front Immunol (2011) 2:29. doi:10.3389/fimmu.2011.00029 
139. Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new 
tricks. Nat Rev Cancer (2016) 16(1):7–19. doi:10.1038/nrc.2015.5 
140. Krockenberger M, Dombrowski Y, Weidler C, Ossadnik M, Honig A, Hausler 
S, et al. Macrophage migration inhibitory factor contributes to the immune 
escape of ovarian cancer by down-regulating NKG2D. J Immunol (2008) 
180(11):7338–48. doi:10.4049/jimmunol.180.11.7338
141. Zhou Y, Xu Y, Chen L, Xu B, Wu C, Jiang J. B7-H6 expression correlates with 
cancer progression and patient’s survival in human ovarian cancer. Int J Clin 
Exp Pathol (2015) 8(8):9428–33. 
142. Pesce S, Tabellini G, Cantoni C, Patrizi O, Coltrini D, Rampinelli F, et  al. 
B7-H6-mediated downregulation of NKp30 in NK cells contributes to 
ovarian carcinoma immune escape. Oncoimmunology (2015) 4(4):e1001224. 
doi:10.1080/2162402X.2014.1001224 
143. Wong JL, Berk E, Edwards RP, Kalinski P. IL-18-primed helper NK cells 
collaborate with dendritic cells to promote recruitment of effector CD8+ 
T cells to the tumor microenvironment. Cancer Res (2013) 73(15):4653–62. 
doi:10.1158/0008-5472.CAN-12-4366 
144. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, 
Regnani G, et  al. Intratumoral T cells, recurrence, and survival in epi-
thelial ovarian cancer. N Engl J Med (2003) 348(3):203–13. doi:10.1056/
NEJMoa020177 
145. Hwang WT, Adams SF, Tahirovic E, Hagemann IS, Coukos G. Prognostic 
significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. 
Gynecol Oncol (2012) 124(2):192–8. doi:10.1016/j.ygyno.2011.09.039 
146. Gajewski TF. The next hurdle in cancer immunotherapy: overcoming 
the non-T-cell-inflamed tumor microenvironment. Semin Oncol (2015) 
42(4):663–71. doi:10.1053/j.seminoncol.2015.05.011 
147. Kaech SM, Cui W. Transcriptional control of effector and memory CD8+ 
T cell differentiation. Nat Rev Immunol (2012) 12(11):749–61. doi:10.1038/
nri3307 
148. Huber M, Lohoff M. IRF4 at the crossroads of effector T-cell fate decision. Eur 
J Immunol (2014) 44(7):1886–95. doi:10.1002/eji.201344279 
149. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et  al. 
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/
regulatory T cell ratio are associated with favorable prognosis in ovarian 
cancer. Proc Natl Acad Sci U S A (2005) 102(51):18538–43. doi:10.1073/pnas. 
0509182102 
150. Webb JR, Milne K, Watson P, Deleeuw RJ, Nelson BH. Tumor-infiltrating 
lymphocytes expressing the tissue resident memory marker CD103 are 
associated with increased survival in high-grade serous ovarian cancer. Clin 
Cancer Res (2014) 20(2):434–44. doi:10.1158/1078-0432.CCR-13-1877 
151. Komdeur FL, Wouters MC, Workel HH, Tijans AM, Terwindt AL, Brunekreeft 
KL, et al. CD103+ intraepithelial T cells in high-grade serous ovarian cancer 
are phenotypically diverse TCRalphabeta+ CD8alphabeta+ T cells that can 
be targeted for cancer immunotherapy. Oncotarget (2016) 7(46):75130–44. 
doi:10.18632/oncotarget.12077 
20
Worzfeld et al. The Microenvironment of Ovarian Cancer
Frontiers in Oncology | www.frontiersin.org February 2017 | Volume 7 | Article 24
152. Preston CC, Maurer MJ, Oberg AL, Visscher DW, Kalli KR, Hartmann LC, 
et  al. The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- 
T cells correlate with poor clinical outcome in human serous ovarian 
cancer. PLoS One (2013) 8(11):e80063. doi:10.1371/journal.pone. 
0080063 
153. Burzyn D, Benoist C, Mathis D. Regulatory T cells in nonlymphoid tissues. 
Nat Immunol (2013) 14(10):1007–13. doi:10.1038/ni.2683 
154. Liu C, Workman CJ, Vignali DA. Targeting regulatory T cells in tumors. FEBS 
J (2016) 283(14):2731–48. doi:10.1111/febs.13656 
155. Landskron J, Helland O, Torgersen KM, Aandahl EM, Gjertsen BT, Bjorge 
L, et al. Activated regulatory and memory T-cells accumulate in malignant 
ascites from ovarian carcinoma patients. Cancer Immunol Immunother 
(2015) 64(3):337–47. doi:10.1007/s00262-014-1636-6 
156. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, et al. Regulatory 
CD4(+)CD25(+) T cells in tumors from patients with early-stage non-
small cell lung cancer and late-stage ovarian cancer. Cancer Res (2001) 
61(12):4766–72. 
157. Hermans C, Anz D, Engel J, Kirchner T, Endres S, Mayr D. Analysis of 
FoxP3+ T-regulatory cells and CD8+ T-cells in ovarian carcinoma: location 
and tumor infiltration patterns are key prognostic markers. PLoS One (2014) 
9(11):e111757. doi:10.1371/journal.pone.0111757 
158. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific 
recruitment of regulatory T cells in ovarian carcinoma fosters immune privi-
lege and predicts reduced survival. Nat Med (2004) 10(9):942–9. doi:10.1038/
nm1093 
159. Chang DK, Peterson E, Sun J, Goudie C, Drapkin RI, Liu JF, et  al. Anti-
CCR4 monoclonal antibody enhances antitumor immunity by modulating 
tumor-infiltrating Tregs in an ovarian cancer xenograft humanized 
mouse model. Oncoimmunology (2016) 5(3):e1090075. doi:10.1080/21624
02X.2015.1090075 
160. Mittrucker HW, Visekruna A, Huber M. Heterogeneity in the differentiation 
and function of CD8(+) T cells. Arch Immunol Ther Exp (Warsz) (2014) 
62(6):449–58. doi:10.1007/s00005-014-0293-y 
161. Wu M, Chen X, Lou J, Zhang S, Zhang X, Huang L, et al. TGF-beta1 con-
tributes to CD8+ Treg induction through p38 MAPK signaling in ovarian 
cancer microenvironment. Oncotarget (2016) 7(28):44534–44. doi:10.18632/
oncotarget.10003 
162. Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, et  al. 
Immunologic and clinical effects of antibody blockade of cytotoxic 
T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. 
Proc Natl Acad Sci U S A (2008) 105(8):3005–10. doi:10.1073/pnas. 
0712237105 
163. Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, et al. 
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated 
by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A (2010) 
107(17):7875–80. doi:10.1073/pnas.1003345107 
164. Huang RY, Eppolito C, Lele S, Shrikant P, Matsuzaki J, Odunsi K. LAG3 and 
PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and 
dampen antitumor immunity in a murine ovarian cancer model. Oncotarget 
(2015) 6(29):27359–77. doi:10.18632/oncotarget.4751 
165. Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama 
T, et  al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, 
in patients with platinum-resistant ovarian cancer. J Clin Oncol (2015) 
33(34):4015–22. doi:10.1200/JCO.2015.62.3397 
166. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and 
co-inhibition. Nat Rev Immunol (2013) 13(4):227–42. doi:10.1038/nri3405 
167. Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. 
Nat Rev Immunol (2015) 15(8):486–99. doi:10.1038/nri3862 
168. Speiser DE, Utzschneider DT, Oberle SG, Munz C, Romero P, Zehn D. 
T cell differentiation in chronic infection and cancer: functional adaptation 
or exhaustion? Nat Rev Immunol (2014) 14(11):768–74. doi:10.1038/nri3740 
169. Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3 – potential mech-
anisms of action. Nat Rev Immunol (2015) 15(1):45–56. doi:10.1038/nri3790 
170. Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immuno-
therapy and new immunomodulatory targets. Nat Rev Drug Discov (2015) 
14(8):561–84. doi:10.1038/nrd4591 
171. Yang YF, Zou JP, Mu J, Wijesuriya R, Ono S, Walunas T, et  al. Enhanced 
induction of antitumor T-cell responses by cytotoxic T lymphocyte- associated 
molecule-4 blockade: the effect is manifested only at the restricted 
tumor-bearing stages. Cancer Res (1997) 57(18):4036–41. 
172. Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Cell Res 
(2017) 27(1):109–18. doi:10.1038/cr.2016.151 
173. Bulliard Y, Jolicoeur R, Windman M, Rue SM, Ettenberg S, Knee DA, 
et al. Activating Fc gamma receptors contribute to the antitumor activities 
of immunoregulatory receptor-targeting antibodies. J Exp Med (2013) 
210(9):1685–93. doi:10.1084/jem.20130573 
174. Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce 
F, et  al. Fc-dependent depletion of tumor-infiltrating regulatory T cells 
co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 
(2013) 210(9):1695–710. doi:10.1084/jem.20130579 
175. Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, Srinivasan M, 
et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity 
through reduction of intratumoral regulatory T cells. Cancer Immunol Res 
(2013) 1(1):32–42. doi:10.1158/2326-6066.CIR-13-0013 
176. Simpson-Abelson MR, Loyall JL, Lehman HK, Barnas JL, Minderman 
H, O’Loughlin KL, et  al. Human ovarian tumor ascites fluids rapidly and 
reversibly inhibit T cell receptor-induced NF-kappaB and NFAT signaling in 
tumor-associated T cells. Cancer Immun (2013) 13:14. 
177. Xu S, Tao Z, Hai B, Liang H, Shi Y, Wang T, et  al. miR-424(322) reverses 
chemoresistance via T-cell immune response activation by blocking the 
PD-L1 immune checkpoint. Nat Commun (2016) 7:11406. doi:10.1038/
ncomms11406 
178. Peng D, Kryczek I, Nagarsheth N, Zhao L, Wei S, Wang W, et al. Epigenetic 
silencing of TH1-type chemokines shapes tumour immunity and immuno-
therapy. Nature (2015) 527(7577):249–53. doi:10.1038/nature15520 
179. Chang CH, Pearce EL. Emerging concepts of T cell metabolism as a target 
of immunotherapy. Nat Immunol (2016) 17(4):364–8. doi:10.1038/ni.3415 
180. Chang CH, Qiu J, O’Sullivan D, Buck MD, Noguchi T, Curtis JD, et  al. 
Metabolic competition in the tumor microenvironment is a driver of 
cancer progression. Cell (2015) 162(6):1229–41. doi:10.1016/j.cell.2015. 
08.016 
181. Ho PC, Bihuniak JD, Macintyre AN, Staron M, Liu X, Amezquita R, et al. 
Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell 
responses. Cell (2015) 162(6):1217–28. doi:10.1016/j.cell.2015.08.012 
182. Eil R, Vodnala SK, Clever D, Klebanoff CA, Sukumar M, Pan JH, et al. Ionic 
immune suppression within the tumour microenvironment limits T cell 
effector function. Nature (2016) 537(7621):539–43. doi:10.1038/nature19364 
183. Niedbala MJ, Crickard K, Bernacki RJ. Interactions of human ovarian tumor 
cells with human mesothelial cells grown on extracellular matrix. An in vitro 
model system for studying tumor cell adhesion and invasion. Exp Cell Res 
(1985) 160(2):499–513. 
184. Birbeck MS, Wheatley DN. An electron microscopic study of the invasion 
of ascites tumor cells into the abdominal wall. Cancer Res (1965) 25:490–7. 
185. Burleson KM, Casey RC, Skubitz KM, Pambuccian SE, Oegema TR Jr, 
Skubitz AP. Ovarian carcinoma ascites spheroids adhere to extracellular 
matrix components and mesothelial cell monolayers. Gynecol Oncol (2004) 
93(1):170–81. doi:10.1016/j.ygyno.2003.12.034 
186. Lessan K, Aguiar DJ, Oegema T, Siebenson L, Skubitz AP. CD44 and beta1 
integrin mediate ovarian carcinoma cell adhesion to peritoneal mesothelial 
cells. Am J Pathol (1999) 154(5):1525–37. 
187. Strobel T, Cannistra SA. Beta1-integrins partly mediate binding of ovarian 
cancer cells to peritoneal mesothelium in  vitro. Gynecol Oncol (1999) 
73(3):362–7. doi:10.1006/gyno.1999.5388 
188. Cannistra SA, Kansas GS, Niloff J, DeFranzo B, Kim Y, Ottensmeier C. 
Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly 
mediated by CD44H. Cancer Res (1993) 53(16):3830–8. 
189. Strobel T, Swanson L, Cannistra SA. In vivo inhibition of CD44 limits 
intra-abdominal spread of a human ovarian cancer xenograft in nude mice: 
a novel role for CD44 in the process of peritoneal implantation. Cancer Res 
(1997) 57(7):1228–32. 
190. Davidowitz RA, Selfors LM, Iwanicki MP, Elias KM, Karst A, Piao H, et al. 
Mesenchymal gene program-expressing ovarian cancer spheroids exhibit 
enhanced mesothelial clearance. J Clin Invest (2014) 124(6):2611–25. 
doi:10.1172/JCI69815 
191. Sawada K, Mitra AK, Radjabi AR, Bhaskar V, Kistner EO, Tretiakova M, 
et  al. Loss of E-cadherin promotes ovarian cancer metastasis via alpha 
21
Worzfeld et al. The Microenvironment of Ovarian Cancer
Frontiers in Oncology | www.frontiersin.org February 2017 | Volume 7 | Article 24
5-integrin, which is a therapeutic target. Cancer Res (2008) 68(7):2329–39. 
doi:10.1158/0008-5472.CAN-07-5167 
192. Mould AP, Askari JA, Aota S, Yamada KM, Irie A, Takada Y, et al. Defining the 
topology of integrin alpha5beta1-fibronectin interactions using inhibitory 
anti-alpha5 and anti-beta1 monoclonal antibodies. Evidence that the synergy 
sequence of fibronectin is recognized by the amino-terminal repeats of the 
alpha5 subunit. J Biol Chem (1997) 272(28):17283–92. 
193. Kenny HA, Kaur S, Coussens LM, Lengyel E. The initial steps of ovarian 
cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and 
fibronectin. J Clin Invest (2008) 118(4):1367–79. doi:10.1172/JCI33775 
194. Iwanicki MP, Davidowitz RA, Ng MR, Besser A, Muranen T, Merritt M, 
et  al. Ovarian cancer spheroids use myosin-generated force to clear the 
mesothelium. Cancer Discov (2011) 1(2):144–57. doi:10.1158/2159-8274.
CD-11-0010 
195. Heath RM, Jayne DG, O’Leary R, Morrison EE, Guillou PJ. Tumour-induced 
apoptosis in human mesothelial cells: a mechanism of peritoneal invasion by 
Fas ligand/Fas interaction. Br J Cancer (2004) 90(7):1437–42. doi:10.1038/
sj.bjc.6601635 
196. Kenny HA, Chiang CY, White EA, Schryver EM, Habis M, Romero IL, 
et  al. Mesothelial cells promote early ovarian cancer metastasis through 
fibronectin secretion. J Clin Invest (2014) 124(10):4614–28. doi:10.1172/ 
JCI74778 
197. Ksiazek K, Mikula-Pietrasik J, Korybalska K, Dworacki G, Jorres A, Witowski 
J. Senescent peritoneal mesothelial cells promote ovarian cancer cell adhe-
sion: the role of oxidative stress-induced fibronectin. Am J Pathol (2009) 
174(4):1230–40. doi:10.2353/ajpath.2009.080613 
198. Mitra AK, Sawada K, Tiwari P, Mui K, Gwin K, Lengyel E. Ligand-independent 
activation of c-Met by fibronectin and alpha(5)beta(1)-integrin regulates 
ovarian cancer invasion and metastasis. Oncogene (2011) 30(13):1566–76. 
doi:10.1038/onc.2010.532 
199. Naylor MS, Stamp GW, Davies BD, Balkwill FR. Expression and activity 
of MMPS and their regulators in ovarian cancer. Int J Cancer (1994) 
58(1):50–6. 
200. Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al. The 
prognostic landscape of genes and infiltrating immune cells across human 
cancers. Nat Med (2015) 21(8):938–45. doi:10.1038/nm.3909 
201. Fishman DA, Liu Y, Ellerbroek SM, Stack MS. Lysophosphatidic acid pro-
motes matrix metalloproteinase (MMP) activation and MMP-dependent 
invasion in ovarian cancer cells. Cancer Res (2001) 61(7):3194–9. 
202. Kortlever RM, Brummelkamp TR, van Meeteren LA, Moolenaar WH, 
Bernards R. Suppression of the p53-dependent replicative senescence 
response by lysophosphatidic acid signaling. Mol Cancer Res (2008) 
6(9):1452–60. doi:10.1158/1541-7786.MCR-08-0066 
203. Hu YL, Tee MK, Goetzl EJ, Auersperg N, Mills GB, Ferrara N, et  al. 
Lysophosphatidic acid induction of vascular endothelial growth factor 
expression in human ovarian cancer cells. J Natl Cancer Inst (2001) 
93(10):762–7. doi:10.1093/jnci/93.10.762 
204. Yamamoto S, Konishi I, Mandai M, Kuroda H, Komatsu T, Nanbu K, 
et  al. Expression of vascular endothelial growth factor (VEGF) in 
epithelial ovarian neoplasms: correlation with clinicopathology and 
patient survival, and analysis of serum VEGF levels. Br J Cancer (1997) 
76(9):1221–7. 
205. Hartenbach EM, Olson TA, Goswitz JJ, Mohanraj D, Twiggs LB, Carson 
LF, et  al. Vascular endothelial growth factor (VEGF) expression and sur-
vival in human epithelial ovarian carcinomas. Cancer Lett (1997) 121(2): 
169–75. 
206. Kassim SK, El-Salahy EM, Fayed ST, Helal SA, Helal T, Azzam Eel D, et al. 
Vascular endothelial growth factor and interleukin-8 are associated with 
poor prognosis in epithelial ovarian cancer patients. Clin Biochem (2004) 
37(5):363–9. doi:10.1016/j.clinbiochem.2004.01.014 
207. Colombo N, Conte PF, Pignata S, Raspagliesi F, Scambia G. Bevacizumab in 
ovarian cancer: focus on clinical data and future perspectives. Crit Rev Oncol 
Hematol (2016) 97:335–48. doi:10.1016/j.critrevonc.2015.08.017 
208. Olson TA, Mohanraj D, Carson LF, Ramakrishnan S. Vascular permeability 
factor gene expression in normal and neoplastic human ovaries. Cancer Res 
(1994) 54(1):276–80. 
209. Hagemann T, Wilson J, Burke F, Kulbe H, Li NF, Pluddemann A, et al. Ovarian 
cancer cells polarize macrophages toward a tumor-associated phenotype. 
J Immunol (2006) 176(8):5023–32. doi:10.4049/jimmunol.176.8.5023 
210. Stadlmann S, Amberger A, Pollheimer J, Gastl G, Offner FA, 
Margreiter R, et  al. Ovarian carcinoma cells and IL-1beta-activated 
human peritoneal mesothelial cells are possible sources of vascular 
endothelial growth factor in inflammatory and malignant peritoneal 
effusions. Gynecol Oncol (2005) 97(3):784–9. doi:10.1016/j.ygyno.2005. 
02.017 
211. Ziogas AC, Gavalas NG, Tsiatas M, Tsitsilonis O, Politi E, Terpos E, et  al. 
VEGF directly suppresses activation of T cells from ovarian cancer patients 
and healthy individuals via VEGF receptor Type 2. Int J Cancer (2012) 
130(4):857–64. doi:10.1002/ijc.26094 
212. Horiuchi A, Imai T, Shimizu M, Oka K, Wang C, Nikaido T, et  al. 
Hypoxia-induced changes in the expression of VEGF, HIF-1 alpha and cell 
cycle-related molecules in ovarian cancer cells. Anticancer Res (2002) 22(5): 
2697–702.
213. Skinner HD, Zheng JZ, Fang J, Agani F, Jiang BH. Vascular endothelial 
growth factor transcriptional activation is mediated by hypoxia-inducible 
factor 1alpha, HDM2, and p70S6K1 in response to phosphatidylinositol 
3-kinase/AKT signaling. J Biol Chem (2004) 279(44):45643–51. doi:10.1074/
jbc.M404097200 
214. Masoumi Moghaddam S, Amini A, Morris DL, Pourgholami MH. Significance 
of vascular endothelial growth factor in growth and peritoneal dissemination 
of ovarian cancer. Cancer Metastasis Rev (2012) 31(1–2):143–62. doi:10.1007/
s10555-011-9337-5 
215. Wang FQ, So J, Reierstad S, Fishman DA. Vascular endothelial growth fac-
tor-regulated ovarian cancer invasion and migration involves expression and 
activation of matrix metalloproteinases. Int J Cancer (2006) 118(4):879–88. 
doi:10.1002/ijc.21421 
216. Zhang A, Meng L, Wang Q, Xi L, Chen G, Wang S, et al. Enhanced in vitro 
invasiveness of ovarian cancer cells through up-regulation of VEGF and 
induction of MMP-2. Oncol Rep (2006) 15(4):831–6. doi:10.3892/or.15.4.831 
217. Bamias A, Koutsoukou V, Terpos E, Tsiatas ML, Liakos C, Tsitsilonis O, 
et  al. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) 
regulatory T cells with VEGF and TNFalpha in ascites from advanced ovar-
ian cancer: association with platinum resistance and prognosis in patients 
receiving first-line, platinum-based chemotherapy. Gynecol Oncol (2008) 
108(2):421–7. doi:10.1016/j.ygyno.2007.10.018 
218. Rodriguez GC, Haisley C, Hurteau J, Moser TL, Whitaker R, Bast RC Jr, 
et  al. Regulation of invasion of epithelial ovarian cancer by transforming 
growth factor-beta. Gynecol Oncol (2001) 80(2):245–53. doi:10.1006/gyno. 
2000.6042 
219. Negus RP, Stamp GW, Relf MG, Burke F, Malik ST, Bernasconi S, et al. The 
detection and localization of monocyte chemoattractant protein-1 (MCP-1) 
in human ovarian cancer. J Clin Invest (1995) 95(5):2391–6. doi:10.1172/
JCI117933 
220. Wang Y, Li L, Guo X, Jin X, Sun W, Zhang X, et al. Interleukin-6 signaling reg-
ulates anchorage-independent growth, proliferation, adhesion and invasion 
in human ovarian cancer cells. Cytokine (2012) 59(2):228–36. doi:10.1016/ 
j.cyto.2012.04.020 
221. Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, et  al. 
Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and 
JNK. J Immunol (2005) 175(2):1197–205. doi:10.4049/jimmunol.175.2.1197 
222. Malik ST, Griffin DB, Fiers W, Balkwill FR. Paradoxical effects of tumour 
necrosis factor in experimental ovarian cancer. Int J Cancer (1989) 
44(5):918–25. 
223. Barbolina MV, Kim M, Liu Y, Shepard J, Belmadani A, Miller RJ, et  al. 
Microenvironmental regulation of chemokine (C-X-C-motif) receptor 4 in 
ovarian carcinoma. Mol Cancer Res (2010) 8(5):653–64. doi:10.1158/1541-
7786.MCR-09-0463 
224. Kajiyama H, Shibata K, Terauchi M, Ino K, Nawa A, Kikkawa F. Involvement 
of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of 
epithelial ovarian carcinoma. Int J Cancer (2008) 122(1):91–9. doi:10.1002/ 
ijc.23083 
225. Dijkgraaf EM, Heusinkveld M, Tummers B, Vogelpoel LT, Goedemans 
R, Jha V, et  al. Chemotherapy alters monocyte differentiation to favor 
generation of cancer-supporting M2 macrophages in the tumor microenvi-
ronment. Cancer Res (2013) 73(8):2480–92. doi:10.1158/0008-5472.CAN- 
12-3542 
226. Wang D, Zhao Z, Caperell-Grant A, Yang G, Mok SC, Liu J, et  al. S1P 
differentially regulates migration of human ovarian cancer and human 
22
Worzfeld et al. The Microenvironment of Ovarian Cancer
Frontiers in Oncology | www.frontiersin.org February 2017 | Volume 7 | Article 24
ovarian surface epithelial cells. Mol Cancer Ther (2008) 7(7):1993–2002. 
doi:10.1158/1535-7163.MCT-08-0088 
227. Park KS, Kim MK, Lee HY, Kim SD, Lee SY, Kim JM, et al. S1P stimulates 
chemotactic migration and invasion in OVCAR3 ovarian cancer cells. 
Biochem Biophys Res Commun (2007) 356(1):239–44. doi:10.1016/j.bbrc. 
2007.02.112 
228. Hong G, Baudhuin LM, Xu Y. Sphingosine-1-phosphate modulates 
growth and adhesion of ovarian cancer cells. FEBS Lett (1999) 460(3): 
513–8. 
229. Devine KM, Smicun Y, Hope JM, Fishman DA. S1P induced changes in 
epithelial ovarian cancer proteolysis, invasion, and attachment are medi-
ated by Gi and Rac. Gynecol Oncol (2008) 110(2):237–45. doi:10.1016/ 
j.ygyno.2008.04.013 
230. Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt 
MR, et al. Adipocytes promote ovarian cancer metastasis and provide energy 
for rapid tumor growth. Nat Med (2011) 17(11):1498–503. doi:10.1038/
nm.2492 
231. Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H. TLR signaling by 
tumor and immune cells: a double-edged sword. Oncogene (2008) 27(2): 
218–24. doi:10.1038/sj.onc.1210904 
232. Ridnour LA, Cheng RY, Switzer CH, Heinecke JL, Ambs S, Glynn S, et al. 
Molecular pathways: toll-like receptors in the tumor microenvironment 
– poor prognosis or new therapeutic opportunity. Clin Cancer Res (2013) 
19(6):1340–6. doi:10.1158/1078-0432.CCR-12-0408 
233. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor 
stroma generation and wound healing. N Engl J Med (1986) 315(26):1650–9. 
doi:10.1056/NEJM198612253152606 
234. Dvorak HF. Tumors: wounds that do not heal-redux. Cancer Immunol Res 
(2015) 3(1):1–11. doi:10.1158/2326-6066.CIR-14-0209 
235. Gill SE, Parks WC. Metalloproteinases and their inhibitors: regulators of 
wound healing. Int J Biochem Cell Biol (2008) 40(6–7):1334–47. doi:10.1016/ 
j.biocel.2007.10.024 
236. Li HS, Watowich SS. Innate immune regulation by STAT-mediated tran-
scriptional mechanisms. Immunol Rev (2014) 261(1):84–101. doi:10.1111/
imr.12198 
237. Hoffmann A, Baltimore D. Circuitry of nuclear factor kappaB signal-
ing. Immunol Rev (2006) 210:171–86. doi:10.1111/j.0105-2896.2006. 
00375.x 
238. Grivennikov SI, Karin M. Dangerous liaisons: STAT3 and NF-kappaB 
collaboration and crosstalk in cancer. Cytokine Growth Factor Rev (2010) 
21(1):11–9. doi:10.1016/j.cytogfr.2009.11.005 
239. Giuntoli RL II, Webb TJ, Zoso A, Rogers O, Diaz-Montes TP, Bristow RE, 
et  al. Ovarian cancer-associated ascites demonstrates altered immune 
environment: implications for antitumor immunity. Anticancer Res (2009) 
29(8):2875–84. 
240. Michel T, Hentges F, Zimmer J. Consequences of the crosstalk between 
monocytes/macrophages and natural killer cells. Front Immunol (2012) 
3:403. doi:10.3389/fimmu.2012.00403 
241. Barbulescu K, Becker C, Schlaak JF, Schmitt E, Meyer zum Buschenfelde KH, 
Neurath MF, et al. IL-12 and IL-18 differentially regulate the transcriptional 
activity of the human IFN-gamma promoter in primary CD4+ T lympho-
cytes. J Immunol (1998) 160(8):3642–7.
242. Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and 
resistance to rejection of tumor cells expressing dominant negative IFN 
gamma receptors. Immunity (1994) 1(6):447–56. 
243. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, et  al. 
Demonstration of an interferon gamma-dependent tumor surveillance 
system in immunocompetent mice. Proc Natl Acad Sci U S A (1998) 
95(13):7556–61. 
244. Snijders A, Hilkens CM, van der Pouw Kraan TC, Engel M, Aarden LA, 
Kapsenberg ML. Regulation of bioactive IL-12 production in lipopolysac-
charide-stimulated human monocytes is determined by the expression of the 
p35 subunit. J Immunol (1996) 156(3):1207–12. 
245. Hu X, Chakravarty SD, Ivashkiv LB. Regulation of interferon and Toll-like 
receptor signaling during macrophage activation by opposing feedforward 
and feedback inhibition mechanisms. Immunol Rev (2008) 226:41–56. 
doi:10.1111/j.1600-065X.2008.00707.x 
246. Ramirez-Carrozzi VR, Nazarian AA, Li CC, Gore SL, Sridharan R, Imbalzano 
AN, et  al. Selective and antagonistic functions of SWI/SNF and Mi-2beta 
nucleosome remodeling complexes during an inflammatory response. Genes 
Dev (2006) 20(3):282–96. doi:10.1101/gad.1383206 
247. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I. 
Immunosuppressive effects of apoptotic cells. Nature (1997) 390(6658): 
350–1. doi:10.1038/37022 
248. Fritsche KL, Byrge M, Feng C. Dietary omega-3 polyunsaturated fatty acids 
from fish oil reduce interleukin-12 and interferon-gamma production in 
mice. Immunol Lett (1999) 65(3):167–73. 
249. Lang R, Patel D, Morris JJ, Rutschman RL, Murray PJ. Shaping gene expres-
sion in activated and resting primary macrophages by IL-10. J Immunol 
(2002) 169(5):2253–63. doi:10.4049/jimmunol.169.5.2253 
250. Huynh ML, Malcolm KC, Kotaru C, Tilstra JA, Westcott JY, Fadok VA, 
et  al. Defective apoptotic cell phagocytosis attenuates prostaglandin E2 
and 15-hydroxyeicosatetraenoic acid in severe asthma alveolar macro-
phages. Am J Respir Crit Care Med (2005) 172(8):972–9. doi:10.1164/rccm. 
200501-035OC 
251. Murray PJ. The primary mechanism of the IL-10-regulated antiinflammatory 
response is to selectively inhibit transcription. Proc Natl Acad Sci U S A (2005) 
102(24):8686–91. doi:10.1073/pnas.0500419102 
252. Melisi D, Chiao PJ. NF-kappa B as a target for cancer therapy. Expert Opin 
Ther Targets (2007) 11(2):133–44. doi:10.1517/14728222.11.2.133 
253. Jinawath N, Vasoontara C, Jinawath A, Fang X, Zhao K, Yap KL, et  al. 
Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in 
carboplatin resistant ovarian carcinoma. PLoS One (2010) 5(6):e11198. 
doi:10.1371/journal.pone.0011198 
254. Smallie T, Ricchetti G, Horwood NJ, Feldmann M, Clark AR, Williams 
LM. IL-10 inhibits transcription elongation of the human TNF gene in 
primary macrophages. J Exp Med (2010) 207(10):2081–8. doi:10.1084/ 
jem.20100414 
255. Smith AM, Qualls JE, O’Brien K, Balouzian L, Johnson PF, Schultz-Cherry 
S, et al. A distal enhancer in Il12b is the target of transcriptional repression 
by the STAT3 pathway and requires the basic leucine zipper (B-ZIP) pro-
tein NFIL3. J Biol Chem (2011) 286(26):23582–90. doi:10.1074/jbc.M111. 
249235 
256. Natoli G. NF-kappaB and chromatin: ten years on the path from basic 
mechanisms to candidate drugs. Immunol Rev (2012) 246(1):183–92. 
doi:10.1111/j.1600-065X.2012.01103.x 
257. Herve J, Dubreil L, Tardif V, Terme M, Pogu S, Anegon I, et al. beta2-Ad-
renoreceptor agonist inhibits antigen cross-presentation by dendritic cells. 
J Immunol (2013) 190(7):3163–71. doi:10.4049/jimmunol.1201391 
258. O’Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence 
A. The JAK-STAT pathway: impact on human disease and therapeutic 
intervention. Annu Rev Med (2015) 66:311–28. doi:10.1146/annurev-med- 
051113-024537 
259. Birge RB, Boeltz S, Kumar S, Carlson J, Wanderley J, Calianese D, et  al. 
Phosphatidylserine is a global immunosuppressive signal in efferocytosis, 
infectious disease, and cancer. Cell Death Differ (2016) 23(6):962–78. 
doi:10.1038/cdd.2016.11 
260. Natoli G, Saccani S, Bosisio D, Marazzi I. Interactions of NF-kappaB with 
chromatin: the art of being at the right place at the right time. Nat Immunol 
(2005) 6(5):439–45. doi:10.1038/ni1196 
261. Sanjabi S, Hoffmann A, Liou HC, Baltimore D, Smale ST. Selective 
requirement for c-Rel during IL-12 P40 gene induction in macrophages. 
Proc Natl Acad Sci U S A (2000) 97(23):12705–10. doi:10.1073/pnas. 
230436397 
262. Sanjabi S, Williams KJ, Saccani S, Zhou L, Hoffmann A, Ghosh G, et  al. 
A c-Rel subdomain responsible for enhanced DNA-binding affinity and 
selective gene activation. Genes Dev (2005) 19(18):2138–51. doi:10.1101/
gad.1329805 
263. Ruan Q, Kameswaran V, Tone Y, Li L, Liou HC, Greene MI, et al. Development 
of Foxp3(+) regulatory T cells is driven by the c-Rel enhanceosome. Immunity 
(2009) 31(6):932–40. doi:10.1016/j.immuni.2009.10.006 
264. Huehn J, Beyer M. Epigenetic and transcriptional control of Foxp3+ 
regulatory T cells. Semin Immunol (2015) 27(1):10–8. doi:10.1016/j.smim. 
2015.02.002 
265. Bhushan S, Tchatalbachev S, Lu Y, Frohlich S, Fijak M, Vijayan V, et  al. 
Differential activation of inflammatory pathways in testicular macrophages 
provides a rationale for their subdued inflammatory capacity. J Immunol 
(2015) 194(11):5455–64. doi:10.4049/jimmunol.1401132 
23
Worzfeld et al. The Microenvironment of Ovarian Cancer
Frontiers in Oncology | www.frontiersin.org February 2017 | Volume 7 | Article 24
266. Guo RX, Qiao YH, Zhou Y, Li LX, Shi HR, Chen KS. Increased staining for 
phosphorylated AKT and nuclear factor-kappaB p65 and their relationship 
with prognosis in epithelial ovarian cancer. Pathol Int (2008) 58(12):749–56. 
doi:10.1111/j.1440-1827.2008.02306.x 
267. Darb-Esfahani S, Sinn BV, Weichert W, Budczies J, Lehmann A, 
Noske A, et  al. Expression of classical NF-kappaB pathway effectors 
in human ovarian carcinoma. Histopathology (2010) 56(6):727–39. 
doi:10.1111/j.1365-2559.2010.03544.x 
268. Alvero AB. Recent insights into the role of NF-kappaB in ovarian carcinogen-
esis. Genome Med (2010) 2(8):56. doi:10.1186/gm177 
269. DiDonato JA, Mercurio F, Karin M. NF-kappaB and the link between 
inflammation and cancer. Immunol Rev (2012) 246(1):379–400. doi:10.1111/ 
j.1600-065X.2012.01099.x 
270. Alberti C, Pinciroli P, Valeri B, Ferri R, Ditto A, Umezawa K, et al. Ligand-
dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via 
the NFkB pathway in advanced-stage epithelial ovarian cancer. Oncogene 
(2012) 31(37):4139–49. doi:10.1038/onc.2011.572 
271. White KL, Rider DN, Kalli KR, Knutson KL, Jarvik GP, Goode EL. Genomics 
of the NF-kappaB signaling pathway: hypothesized role in ovarian cancer. 
Cancer Causes Control (2011) 22(5):785–801. doi:10.1007/s10552-011- 
9745-4 
272. Godwin P, Baird AM, Heavey S, Barr MP, O’Byrne KJ, Gately K. Targeting 
nuclear factor-kappa B to overcome resistance to chemotherapy. Front Oncol 
(2013) 3:120. doi:10.3389/fonc.2013.00120 
273. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. 
Cell (2010) 140(6):883–99. doi:10.1016/j.cell.2010.01.025 
274. Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signalling 
in cancer: new and unexpected biological functions. Nat Rev Cancer (2014) 
14(11):736–46. doi:10.1038/nrc3818 
275. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a lead-
ing role for STAT3. Nat Rev Cancer (2009) 9(11):798–809. doi:10.1038/nrc2734 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2017 Worzfeld, Pogge von Strandmann, Huber, Adhikary, Wagner, 
Reinartz and Müller. This is an open-access article distributed under the terms of 
the Creative Commons Attribution License (CC BY). The use, distribution or repro-
duction in other forums is permitted, provided the original author(s) or licensor are 
credited and that the original publication in this journal is cited, in accordance with 
accepted academic practice. No use, distribution or reproduction is permitted which 
does not comply with these terms.
